US Pat. No. 10,968,213

CYCLOPROPANAMINE COMPOUND AND USE THEREOF

Takeda Pharmaceutical Com...

1. A method for the treatment of hearing loss in a mammal, comprising administering an effective amount of 5-((1R,2R)-2-((cyclopropylmethyl)amino)cyclopropyl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide, or a salt thereof, to the mammal.
US Pat. No. 10,968,469

PROLINE HYDROXYLASES AS WELL AS USES, METHODS AND PRODUCTS INVOLVING THE SAME

F. Hoffmann-La Roche, Inc...

1. A method of hydroxylating pipecolic acid (PA) or L-pipecolic acid (L-PA), comprising contacting the PA or L-PA with a hydroxylase protein, wherein the protein comprises the amino acid sequence of SEQ ID NO:1 or an amino acid sequence of at least 90% identity to SEQ ID NO:1, wherein the protein has pipecolic acid hydroxylase activity, thereby producing hydroxylated pipecolic acids.
US Pat. No. 10,968,470

METHOD FOR PREPARING RUBUSOSIDE

Guilin Layn Natural Ingre...

1. A method for preparing rubusoside, comprising the steps:(1) providing a dry sample of Rubus suatrssimus S. Lee leaves, crushing and passing them through 40-60 mesh sieve, putting the obtained powder material into a flash extractor, in which water at the amount of 18-20 times by weight of the powder is added, extracting for 3 times, 1 minute for each time, and combining all extract solutions to get the total extract solution;
(2) concentrating the total extract solution to a concentrate solution 5 times by weight of the raw leaves, centrifuging the concentrate solution through a disc centrifuge and a tube centrifuge to obtain a centrifugate, and adjusting the centrifugate to pH 5.0-6.0 using an acid solution;
(3) passing the adjusted centrifugate through a macroporous resin column, adjusting the effluent to pH 7.0 using 0.2% sodium hydroxide solution, detecting the content of rubusoside and ending sample loading when the content is >1%; when the loading is completed, washing the column firstly using pure water until the effluent is colorless and clear, secondly using an alkaline solution until the effluent is PH 11 to 12, thirdly using pure water until the effluent is PH 7.0-7.5, fourthly using an acid solution until the effluent is PH 2.0-2.5, and finally using water until the effluent is PH 7.0;
(4) desorbing with 45%-50% ethanol solution, collecting the effluent from the time rubusoside is detected as >1% to the time rubusoside is detected as <1%, and concentrating the effluent under reduced pressure to a concentrate solution of 5 Baume Degrees (°Bé);
(5) adding a biological enzyme to the concentrate solution obtained in step (4), and digesting at a temperature of 45-60° C. for 1-3 hours to obtain an enzymatic hydrolysate;
(6) passing the enzymatic hydrolysate through an organic membrane of 8000 molecular weight under the inlet pressure of 0.45-0.5 MPa, then through an organic membrane of 800 molecular weight under the inlet pressure of 1.8-2.0 MPa to obtain a decolored filtrate;
(7) concentrating the filtrate under reduced pressure to obtain a thick paste of 15 Baume Degrees (°Bé), adding methanol or ethanol as a solvent at an amount 3 times that of the thick paste, crystallizing at 5-11° C. for 8-14 hours, drying the obtained crystal to obtain rubusoside.
US Pat. No. 10,966,933

DRUG DELIVERY SYSTEM

EB IP HYBRITABS B.V., Al...

1. A tablet for sublingual administration of a steroid hormone, said tablet comprising a core, an outer coating on the exterior surface of said tablet and a separation coating that separates said outer coating from said core, wherein:said core comprises 10-45% (w/w) microcrystalline cellulose, 20-70% (w/w) of filler, wherein said filler is calcium sulphate dihydrate or anhydrous dibasic calcium phosphate, or combination thereof, and 0.1-30% (w/w) of a first active ingredient,
said separation coating surrounding the core comprises ethylcellulose as a hydrophobic polymer and microcrystalline cellulose as a hydrophilic substance, wherein the mass ratio of the hydrophobic polymer and the hydrophilic substance is between 1:5 and 5:1,
said outer coating surrounding the separation coating comprises a mixture of said steroid hormone in amorphous form in an amount of between about 0.1-5.0 mg, a coating polymer in an amount of between about 0.25-25 mg, water in an amount of between about 0.0-10% w/w of the outer coating, and a cyclodextrin, or a derivative or polymer thereof, wherein the steroid hormone is testosterone or a functional analog of testosterone.
US Pat. No. 10,968,471

METHOD OF AND ARRANGEMENT FOR TREATING BIOMASS

SULZER MANAGEMENT AG, Wi...

1. A method of continuous biomass hydrolysis in a two-stage hydrolysis process having a pre-hydrolysis reactor and a hydrolysis reactor having a hydrolysis zone and a discharge zone, the method comprising:pretreating fresh biomass by at least one of mechanical/physical, chemical, biological and thermal process or device to open the biomass for hydrolysis treatment;
adding at least one of enzymes, chemicals and nutrients to the biomass at a consistency of 15 wt % or above during the pretreating or thereafter;
mixing the at least one of enzymes, chemicals and nutrients with the fresh biomass during the adding or thereafter to form a mixture thereof;
recycling at least partially hydrolysed biomass slurry from one of the pre-hydrolysis reactor, the discharge zone of the hydrolysis reactor and a discharge line therebetween to be mixed with the mixture of the at least one of enzymes, chemicals and nutrients and the fresh biomass during the mixing or thereafter before adding to the pre-hydrolysis reactor to form a biomass slurry and to reduce the viscosity thereof;
feeding the biomass slurry to the pre-hydrolysis reactor by a centrifugal pump;
enabling the biomass slurry to advance in the pre-hydrolysis reactor in an upward direction as a laminar plug flow and form an at least partially hydrolysed biomass slurry; and
taking the at least partially hydrolysed biomass slurry from the pre-hydrolysis reactor for further processing in the hydrolysis reactor.
US Pat. No. 10,968,472

MULTI-COLOR REPORTER CELLS FOR DETECTING HIV-1

Wisconsin Alumni Research...

1. A method of tracking viral infection of a cell, the method comprising:(a) providing a cell susceptible to infection by a virus in which the cell comprises:
a first nucleic acid encoding a gene that constitutively expresses a first fusion protein, wherein the first fusion protein comprises (i) a first domain susceptible to degradation by a protein from the virus, and (ii) a second domain comprising a first protein fluorophore; and
a second nucleic acid encoding a second fusion protein, wherein the second fusion protein comprises (i) a first domain operably linked to a promoter that is responsive to infection by the virus, and (ii) a second domain comprising a second protein fluorophore;
wherein a fluorescent signal from the first protein fluorophore is down-regulated upon infection of the cell by the virus, and a fluorescent signal from the second protein fluorophore is up-regulated upon infection of the cell by the virus;
(b) exposing the cell to the virus under conditions where the virus can infect the cell;
(c) measuring the fluorescent signals generated by the first protein fluorophore and the second protein fluorophore; and
(d) determining the extent of infection of the cell by the virus by comparing the fluorescent signals measured in step (c) with corresponding signals generated in a corresponding cell not exposed to the virus.
US Pat. No. 10,966,422

PYRETHROID FORMULATIONS

Vive Crop Protection Inc....

1. An aqueous formulation comprising:nanoparticles comprising a polymer and a pyrethroid compound with an average diameter of between about 1 nm and about 500 nm, wherein the pyrethroid compound is associated with the nanoparticles;
an anti-caking agent;
an anti-foaming agent; and
a preservative; and
water and/or liquid fertilizer,
wherein the polymer is a polyelectrolyte copolymer comprised of at least about 50 weight percent methacrylic acid monomers, at least about 75 weight percent acrylic acid monomers, or combinations thereof, and
wherein the polymer and pyrethroid compound together comprise between about 10 parts per million and about 1000 parts per million of the aqueous formulation.
US Pat. No. 10,966,935

METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES

1. A composition for modifying a mucous membrane comprising a first agent that physically interacts or reacts with a protein in said mucous membrane and/or its intimately associated adherent thin film, a second agent that promotes holding an aqueous component of said mucous membrane in place, and a physiologically acceptable carrier, wherein said first agent is a peptide, polypeptide or protein modified to comprise a photoactivatable group and said second agent is a mucin or mucin analog.
US Pat. No. 10,966,424

INSECT REPELLING COMPOSITION

GLOBAL BIOLIFE INC., Bet...

1. A composition for repelling insects comprising, on a weight percent basis:10-20% 2,6-dimethyl-7-octen-2-ol;
0.1-5% 2,6-octadienal, 3,7-dimethyl-;
1-10% benzyl benzoate;
0.01-2% citral;
1-10% hexamethylindanopyran;
10-40% lavender oil;
20-50% Lemon Oil Argentina;
5-15% Lime Oil Distilled Mexican;
0.01-3% limonene; and
5-15% rosemary oil.
US Pat. No. 10,966,937

COMPOSITIONS AND METHODS FOR DELIVERY OF POLYUNSATURATED FATTY ACID DERIVATIVES AND ANALOGS

Cytometix, Inc., Milwauk...

1. An oral delivery system, comprising:a. an enteric coated softgel; and
b. a liquid formulation contained within the enteric coated softgel, the liquid formulation including a vehicle comprising:
i. a combination of purified docosahexaenoic acid (DHA) and purified eicosapentaenoic acid (EPA) in triglyceride forms; and
ii. optionally, one or more of an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH/tonicity adjustment agent; and
iii. a therapeutic that is CMX-020
wherein the vehicle comprises a combination of about 50% (w/w) DHA in triglyceride form and about 32% (w/w) EPA in triglyceride form; and
wherein the CMX-020 is about 2-25% (w/w) of the liquid formulation.
US Pat. No. 10,966,938

COMPOSITION AND METHOD FOR PREVENTING OR TREATING HANGOVER SYMPTOMS

1. A composition for preventing or treating hangover symptoms comprising:a therapeutically effective amount of a cannabidiol;
a therapeutically effective amount of an antioxidant blend comprising a mixture of prickly pear, acai berry extract, and taurine;
a therapeutically effective amount of an detox blend comprising a mixture of milk thistle, dihydromyricetin, glutamine, branched chain amino acids, inositol, and pepper; and
a therapeutically effective amount of a hydration blend comprising a mixture of electrolytes, vitamins, and N-acetyl cysteine.
US Pat. No. 10,968,476

DIRECT QUANTIFICATION OF UNPROCESSED NUCLEIC ACID SAMPLES

LIFE TECHNOLOGIES CORPORA...

1. A method for directly quantifying the presence of DNA without prior application of extraction techniques for Short Tandem Repeat (STR) analysis, the method comprising:contacting an object thought to have been touched by a suspect with a paper to collect any residual nucleic acid left by the suspect on the object, in the collection of evidence for a criminal investigation;
depositing the paper into a vessel;
performing a real-time polymerase chain reaction (rtPCR) within the vessel and detecting the level of fluorescence emitted from the vessel during rtPCR, wherein the level of fluorescence is detected by a charge-coupled device while the paper is in the vessel;
determining the quantity of nucleic acid left by the suspect on the object by correlating the level of fluorescence to the quantity of nucleic acid left by the suspect on the object, wherein the paper is not subjected to nucleic acid extraction techniques;
using direct quantification results to determine the amount of input DNA for STR analysis; and
optionally performing a direct STR amplification.
US Pat. No. 10,966,939

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

GW Research Limited, Cam...

1. A method of treating seizures in a patient with Lennox-Gastaut syndrome or Dravet syndrome, comprising orally administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 95% (w/w), and wherein the CBD is administered in a composition, comprising:(i) CBD at a concentration ranging from about 22.5 mg/mL and about 110 mg/mL;
(ii) ethanol at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL;
(iii) a sweetener at a concentration ranging from about 0.45 mg/mL to about 0.55 mg/mL;
(iv) flavoring at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL;
and (v) a solvent.
US Pat. No. 10,966,940

METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY

INSTITUT NATIONAL DE LA S...

1. A method of reducing the perception of tinnitus in a human having tinnitus comprising administering to the human a therapeutically effective amount of a pharmaceutical composition comprising ketamine over a period of several days.
US Pat. No. 10,968,478

METHODS AND REAGENTS FOR REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION

Global Life Sciences Solu...

1. A method of amplifying an RNA molecule in a biological sample by a reverse transcription PCR (RT-PCR) reaction, wherein the RT-PCR reaction is carried out in a solution comprising:a. a polar aprotic solvent;
b. a serum albumin; and
c. a polyol;
the method comprising:
i) contacting a solid support having a lysis agent embedded thereon with the biological sample containing the RNA molecule, wherein the RNA molecule becomes immobilized on the solid support;
ii) transferring the solid support or a portion thereof with the lysis agent to a reaction vessel; and
iii) performing the RT-PCR reaction in the reaction vessel in the solution in the presence of the solid support with the lysis agent,
wherein the biological sample has not undergone an RNA purification step prior to the RT-PCR reaction.
US Pat. No. 10,966,941

BUPROPION AS A MODULATOR OF DRUG ACTIVITY

ANTECIP BIOVENTURES II LL...

1. A method of increasing dextromethorphan plasma levels in a human being, comprising orally administering, once or twice a day, a dosage form comprising bupropion and dextromethorphan to the human being, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the dosage form contains about 100 mg to about 200 mg of the bupropion and about 40 mg to about 60 mg of the dextromethorphan, wherein the dosage form is orally administered for at least eight consecutive days, wherein on the eighth day that the dosage form is orally administered, the human being has an AUC0-24 of dextromethorphan that is at least about 1300 ng·hr/mL, and wherein on the eighth day that the dosage form is orally administered, the human being has a Cmax of dextromethorphan that is at least about 15 times the Cmax that would be achieved by orally administering the same amount of the dextromethorphan without the bupropion for eight consecutive days.
US Pat. No. 10,968,479

NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTS

The Board of Trustees of ...

1. A method of detecting solid organ transplant derived cell-free nucleic acids in a recipient that has received a solid organ transplant and treating said recipient that has received said solid organ transplant, the method comprising:a. genotyping said recipient to obtain a single nucleotide polymorphism (SNP) profile of said recipient, wherein said SNP profile of said recipient comprises SNPs for which said recipient is homozygous or heterozygous;
b. providing nucleic acids from a biological sample from said recipient after said recipient has received said solid organ transplant, wherein said biological sample is selected from the group consisting of blood, serum and plasma, and wherein said nucleic acids from said biological sample comprise cell-free nucleic acids from said solid organ transplant and from said recipient that has received said solid organ transplant;
c. performing a high-throughput sequencing reaction on said nucleic acids from said biological sample from said recipient to obtain nucleic acid sequence data; and
d. determining an amount of solid organ transplant derived cell-free nucleic acids from said solid organ transplant, wherein said amount of solid organ transplant derived cell-free nucleic acids is determined by detecting a plurality of nucleic acid sequences from said nucleic acid sequence data that differ from said SNP profile of said recipient;
e. administering an immunosuppressant treatment to treat said recipient based on said amount of said solid organ transplant derived cell-free nucleic acids from said solid organ transplant.
US Pat. No. 10,966,942

BUPROPION AS A MODULATOR OF DRUG ACTIVITY

ANTECIP BIOVENTURES II LL...

1. A method of treating major depressive disorder, comprising administering a drug combination to a human being in need thereof, wherein the drug combination comprises:a bupropion, in an amount that is about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form, wherein the bupropion is administered once a day for the first three days and twice a day thereafter for at least 11 days; and
a dextromethorphan, in an amount that is about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form, wherein the dextromethorphan is administered once a day for the first three days and twice a day thereafter for at least 11 days;
wherein the human being is selected for being male; and
wherein the human being experiences a greater reduction in Montgomery-?sberg Depression Rating Scale (MADRS) score after receiving the drug combination, as compared to what would be experienced from receiving the same amount of the bupropion alone.
US Pat. No. 10,968,480

ALPHA-HEMOLYSIN VARIANTS AND USES THEREOF

Roche Sequencing Solution...

1. An ?-hemolysin variant having at least 90% sequence identity to one or more of SEQ ID NOs: 5-14, wherein said amino acid sequence has a set of substitutions relative to SEQ ID NO: 14 comprising at least one of the following substitution combinations:(a) H35G+V149K;
(b) H35G+V149K+E287R;
(c) V149K+E287R;
(d) H35G+T109K;
(e) H35G+P151K;
(f) H35G+V149K+P151K;
(g) H35G+T109K+V149K;
(h) H35G+E111N+M113A+D127G+D128G+T129G+K131G+K147N+V149K;
(i) E111N+M113A+D127G+D128+T129G+K131G+K147N+V149K;
(j) H353G+T109K+V149K+P151K; and
(k) H35G+H144A+V149K+E287R.
US Pat. No. 10,966,430

NATURAL FUNGICIDE COMPOSITION

GRIFFITH FOODS INTERNATIO...

1. A method for treating Black Sigatoka fungus in crops of the Musaceae family comprising:applying a fungicidal composition to the crops comprising an emulsifier, garlic oil, rosemary oil, thyme oil and cinnamon oil in the following percentages by weight:
emulsifier: about 10.0-40.0%
garlic oil: about 2.0-5.0%
rosemary oil: about 0.5-2.5%
thyme oil: about 0.5-2.5%
cinnamon oil: about 0.5-2.5%
peppermint oil: about 0.5-3%.
US Pat. No. 10,966,431

REFRESHMENT TOWEL AND APPLIED SOLUTION

Freedom Towel Holdings, L...

1. A kit for applying at least one of a variety of treatments to a subject, the kit comprising:a base aqueous solution comprising:
up to 98% purified water by volume;
0.005% to 9% alcohol by volume;
0.005% to 3% polysorbate 20 by volume;
0.005% to 5% peg-6 caprylic glycerides by volume;
0.005% to 8% glycerine by volume;
and further comprising of the elements of:
0.005% to 5% lemon grass oil and 0.005% to 5% citronella oil (CAS #8000-29-1) to provide the specialized treatment of insect repelling;
up to 5% of a preservative by volume to provide extended shelf life; 0.003% to 5% mandarin oil by volume;
0.005% to 5% bergamot oil by volume; and
0.003% to 5% grapefruit oil by volume.
US Pat. No. 10,966,944

[2.2.2] BICYCLIC DERIVATIVES AND METHODS OF USE

1. A method for reducing the number or strength of seizures in a human subject suffering from epilepsy and reducing the anomalous neuronal connections in the focus of paroxysmal activity in the brain of the subject, the method comprising the step of orally administering to the subject 50-1200 mg of the bicyclo-[2.2.2]-octane-2-carboxylate salt per day at least until the number or strength of seizures in a human subject is reduced and the anomalous neuronal connections in the focus of paroxysmal activity in the brain of the subject is reduced, the method comprising the step of orally administering to the subject 50-1200 mg of the bicyclo-[2.2.2]-octane-2-carboxylate salt per day at least until the number or strength of seizures in a human subject is reduced.
US Pat. No. 10,966,689

METHOD AND APPARATUS FOR PREDICTING CONCENTRATION OF ANALYTE

SAMSUNG ELECTRONICS CO., ...

1. An apparatus for predicting an in vivo concentration of an analyte, the apparatus comprising:a processor and
a memory connected to the processor, wherein the memory stores a program,
wherein the program is configured to cause the processor to perform;
estimating an in vivo intrinsic spectrum of the analyte by correcting an in vitro intrinsic spectrum of the analyte using a linear combination of the in vitro intrinsic spectrum, a constant function term, and a linear function term, wherein the in vitro intrinsic spectrum of the analyte is a spectrum of the analyte itself obtained from a sample comprised of the analyte dissolved in an aqueous buffer solution and
predicting the in vivo concentration of the analyte by using a net analyte signal based on the estimated in vivo intrinsic spectrum and an in vivo spectrum obtained in a section which is a time duration during which the in vivo concentration of the analyte is not substantially changed.
US Pat. No. 10,966,945

SELECTIVE INHIBITION OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT BY LOW MOLECULAR WEIGHT COMPONENTS OF THE AURIN TRICARBOXYLIC SYNTHETIC COMPLEX

Aurin Biotech Inc., Vanc...

1. A method of selectively inhibiting the membrane attack complex of complement to treat Alzheimer's disease, the method comprising administering an active ingredient of comprising an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, aurin hexacarboxylic acid, and/or esters thereof, wherein the method excludes administration of components of aurin tricarboxylic acid complex greater than or equal to 1 kilodalton in molecular weight, wherein the Alzheimer's disease is associated with host cell self-damage by the membrane attack complex.
US Pat. No. 10,968,483

METHODS AND MATERIALS FOR DETECTING GENETIC OR EPIGENETIC ELEMENTS

Cascade Biosystems, Inc.,...

1. A method for assessing an organism for an epigenetic element, said method comprising:(a) contacting a sample from said organism with a probe nucleic acid comprising a nucleotide sequence complementary to a sequence of a target nucleic acid containing said epigenetic element under conditions wherein, if said target nucleic acid is present in said sample, at least a portion of said target nucleic acid hybridizes to at least a portion of said probe nucleic acid to form a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site, wherein said probe nucleic acid comprises a restriction endonuclease,
(b) contacting said double-stranded portion of nucleic acid with a recognition restriction endonuclease having the ability to cut said double-stranded portion of nucleic acid at said restriction endonuclease cut site under conditions wherein said recognition restriction endonuclease cleaves said double-stranded portion of nucleic acid at said restriction endonuclease cut site, thereby separating a portion of said probe nucleic acid comprising said restriction endonuclease from at least another portion of said probe nucleic acid,
(c) contacting said portion of said probe nucleic acid comprising said restriction endonuclease with signal expansion nucleic acid comprising a label and a double-stranded portion of nucleic acid comprising the restriction endonuclease cut site of said restriction endonuclease under conditions wherein said restriction endonuclease cleaves said signal expansion nucleic acid at said restriction endonuclease cut site of said restriction endonuclease, thereby separating a first portion of said signal expansion nucleic acid from at least another portion of said signal expansion nucleic acid, wherein said first portion comprises said label, and
(d) determining the presence or absence of said first portion using said label, wherein the presence of said first portion indicates that said sample contains said target nucleic acid, and wherein the absence of said first portion indicates that said sample does not contain said target nucleic acid.
US Pat. No. 10,966,946

COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN

CMPD Licensing, LLC, Con...

1. A method of formulating a topical composition for administration to a skin surface, the method comprising:combining between about 10 mg and about 50 mg cannabidiol powder, xylitol powder, and a solution, cream, gel, suspension, or ointment.
US Pat. No. 10,968,484

METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY

The Broad Institute, Inc....

1. A method of treating a subject having cancer comprising measuring in a cancer sample obtained from a subject having cancer(1) expression of one or more resistance markers selected from the group consisting of BDNF, KCNMA1, PAPPA, CCDCl80, RRAS, CLMP, EPHA2, HRH1, SCG5, aTSPAN5, BEX1, TMEM200A, TGM2, CD163L1, S100A16, IGFBP6, ITGA3, LOC100130938, C12orf75, FBN2, CRIM1, COL6A2, and EFNB2 (“R1 markers”), and
(2) expression of
(a) one or more resistance markers selected from the group consisting of DSE, CYR61, CDH13, PODXL, SERPINE1, NRP1, IL1B, BIRC3, AXL, NUAK1, TCF4, COL5A1, NTM, CCL2, IL1A and TPM1 (“R2 markers”), or
(b) one or more sensitive markers selected from the group consisting of IGSF11, FAM167B, MTUS1, GDF15, LINC00518, LRRK2, ID4, CMTM8, KIAA0226L, C11orf96, D4S234E, TBC1D16, TTYH2, LAMA1, PMEL, PROS1, KCNN2, ESRP1, TRIM63, RXRG, PLEKHH1, CPN1, PI15, GNPTAB, and RNF144A (“S1 markers”), or
(c) one or more sensitive markers selected from the group consisting of GYG2, TYR, SLC45A2, PLA1A, ST3GAL6, DCT, CITED1, RAB38, TNFRSF14, GALNT3, MREG, GPM6B, RRAGD, CAPN3, MLANA, and MITF (“S2 markers”), and
identifying the cancer as resistant to a MAPK pathway inhibitor and
administering an effective amount of a non-MAPK pathway inhibitor therapy or a combination of a MAPK pathway inhibitor and a second therapeutic agent to the subject having the resistant cancer, wherein the resistant cancer is characterized as having:
(i) one or more of the R1 markers is up-regulated and
(ii) one or more of the R2 markers is up-regulated or
(iii) one or more of the S1 markers is down-regulated or
(iv) one or more of the S2 markers is down-regulated, or
identifying the cancer as sensitive to a MAPK pathway inhibitor and
administering an effective amount of a MAPK pathway inhibitor to the subject having the sensitive cancer, wherein the sensitive cancer is characterized as having:
(i) one or more of the R1 markers is down-regulated and
(ii) one or more of the R2 markers is down-regulated or
(iii) one or more of the S1 markers is up-regulated or
(iv) one or more of the S2 markers is up-regulated.
US Pat. No. 10,966,434

PROCESS AND SYSTEM FOR DEPOSITING FILLING ON A BISCUIT

Intercontinental Great Br...

1. A method for the production of a food item having a filling, the method comprising:a) conveying a food item to a first filling station, the first filling station having a first rotating stencil with one or more arrays, wherein each array of the first rotating stencil comprises a plurality of filling discharge ports disposed on the circumference of the first rotating stencil;
b) discharging from each array of the first rotating stencil at least one first filling segment having a shape and configuration onto the food item as the food item passes the first filling station;
c) conveying the food item to a second filling station, the second filling station having a second rotating stencil with one or more arrays, wherein each array of the second rotating stencil comprises a plurality of filling discharge ports disposed on the circumference of the second rotating stencil; and
d) discharging from each array of the second rotating stencil at least one further filling segment having a further shape and configuration onto the food item as the food item passes the second filling station, such that each further filling segment discharged at the second filling station does not overlap or disturb any first filling segment discharged at the first filling station.
US Pat. No. 10,966,947

COMBINATION THERAPY COMPRISING AN OMEGA-3 FATTY ACID, A FOLATE SPECIES AND A VITAMIN B12 SPECIES

OXFORD UNIVERSITY INNOVAT...

1. A method of reducing the rate of brain atrophy and atrophy-related decline of cognitive function in a human subject diagnosed with mild cognitive impairment (MCI), and having average or reduced circulating total plasma levels of DHA and EPA, wherein the human subject has a baseline homocysteine level above 9.5 ?mol/L, the method comprising administering to the subject a composition comprising:(i) an amount of DHA and EPA or a derivative thereof sufficient to increase the circulating total plasma concentration of DHA and EPA to greater than 590 ?mol/L;
(ii) a folate species in an amount of from 0.5 mg to 1.5 mg;
(iii) a vitamin B12 species in an amount of 0.09 mg to 2 mg; and
(iv) a vitamin B6 species in an amount of from 15 mg to 30 mg.
US Pat. No. 10,968,485

DETERMINING RISK OF PROSTATE TUMOR AGGRESSIVENESS

The Regents of the Univer...

1. A method for evaluating a biopsy sample to determine a likelihood that a prostate tumor will be aggressive:(a) detecting copy numbers for a set of genomic regions or portions thereof in a nucleic acid sample from a biopsy obtained from a human patient that has a prostate tumor having a Gleason score ?3+3 and clinical stage ?T2, wherein the set of genomic regions or portions thereof comprises genomic regions or portions thereof at human chromosomes 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 and 16q23.1; and
wherein the genomic region or portion thereof at human chromosome 3q26.2 comprises a genomic region or portion thereof at chr3:168805847-168806351, the genomic region or portion thereof at human chromosome 3q26.32 comprises a genomic region or portion thereof at chr3:177272862-177430308, the genomic region or portion thereof at human chromosome 3q26.3 comprises a genomic region or portion thereof at chr3:178951957-178952231, the genomic region or portion thereof at human chromosome 5p15.1 comprises a genomic region or portion thereof at chr5:17412420-17592769, the genomic region or portion thereof at human chromosome 7p22.3 comprises a genomic region or portion thereof at chr7:1062717-1063110 or chr7:2396631-2396986, the genomic region or portion thereof at human chromosome 7q11.22 comprises a genomic region or portion thereof at chr7:69577003-69759243, the genomic region or portion thereof at human chromosome 7q11.23 comprises a genomic region or portion thereof at chr7:73442517-73483030, the genomic region or portion thereof at human chromosome 7q22.1 comprises a genomic region or portion thereof at chr7:100705095-100899914, the genomic region or portion thereof at human chromosome 7q31.31 comprises a genomic region or portion thereof at chr7:117432355-117432817, the genomic region or portion thereof at human chromosome 9q34.1 comprises a genomic region or portion thereof at chr9:132262446-132370055, the genomic region or portion thereof at human chromosome 11p15.4 comprises a genomic region or portion thereof at chr11:2904813-2907001, 17q21.33 comprises a genomic region or portion thereof at chr17:47454237-47654582, the genomic region or portion thereof at human chromosome 17q25.3 comprises a genomic region or portion thereof at chr17:77702278-77862768, the genomic region or portion thereof at human chromosome 22q13.1 comprises a genomic region or portion thereof at chr22:39620241-39631867, the genomic region or portion thereof at human chromosome 4p13 comprises a genomic region or portion thereof at chr4:44558370-44559188, the genomic region or portion thereof at human chromosome 5q13.1 comprises a genomic region or portion thereof at chr5:67803220-67803609, the genomic region or portion thereof at human chromosome 5q14.3 comprises a genomic region or portion thereof at chr5:85936281-86082787, the genomic region or portion thereof at human chromosome 5q21.1 comprises a genomic region or portion thereof at chr5:102652546-102813426, the genomic region or portion thereof at human chromosome 5q21.2 comprises a genomic region or portion thereof at chr5:103047961-103230737, the genomic region or portion thereof at human chromosome 5q21.3 comprises a genomic region or portion thereof at chr5:108476063-108523316, the genomic region or portion thereof at human chromosome 5q23.1 comprises a genomic region or portion thereof at chr5:116987516-116987850, at the genomic region or portion thereof of human chromosome 6q14.1 comprises a genomic region or portion thereof at chr6:79240539-79417494, the genomic region or portion thereof at human chromosome 6q21 comprises a genomic region or portion thereof at chr6:105514625-105687735, the genomic region or portion thereof at human chromosome 6q21 comprises a genomic region or portion thereof at chr6:112401839-112550863, the genomic region or portion thereof at human chromosome 8p22 comprises a genomic region or portion thereof at chr8:15649576-15649945, the genomic region or portion thereof at human chromosome 8p21.2 comprises a genomic region or portion thereof at chr8:25189716-25280826, the genomic region or portion thereof at human chromosome 8p21.2 comprises a genomic region or portion thereof at chr8:26260492-26362544, the genomic region or portion thereof at human chromosome 8p21.2 comprises a genomic region or portion thereof at chr8:26555762-26676439, the genomic region or portion thereof at human chromosome 8p12 comprises a genomic region or portion thereof at chr8:32412399-32572832, the genomic region or portion thereof at human chromosome 10q23.31 comprises a genomic region or portion thereof at chr10:89991491-90075908, the genomic region or portion thereof at human chromosome 13q14.11 comprises a genomic region or portion thereof at chr13:40129477-40205232, the genomic region or portion thereof at human chromosome 13q14.11 comprises a genomic region or portion thereof at chr13:41044273-41044745, the genomic region or portion thereof at human chromosome 13q14.11 comprises a genomic region or portion thereof at chr13:43679675-43868415, the genomic region or portion thereof at human chromosome 13q14.13 comprises a genomic region or portion thereof at chr13:45857696-45858096, the genomic region or portion thereof at human chromosome 13q14.2 comprises a genomic region or portion thereof at chr13:49015662-49140264, the genomic region or portion thereof at human chromosome 13q14.3 comprises a genomic region or portion thereof at chr13:51245126-51245378 and the genomic region or portion thereof at human chromosome 16q23.1 comprises a genomic region or portion thereof at chr16:77158148-77311367;
(b) scoring each genomic region or portion thereof as diseased or normal to generate a copy number score, wherein the scoring is determined based on the copy number in the nucleic acid sample from the biopsy compared to a normal reference copy number of noncancerous tissue; and the genomic region or portion thereof is scored as diseased if there is an increase in copy number at the genomic region or portion thereof located at human chromosome 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, or 22q13.1 in the nucleic acid sample from the biopsy compared to the reference copy number, and if there is a decrease in copy number at the genomic region or portion thereof located at human chromosome 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 or 16q23.1 in the nucleic acid sample from the biopsy compared to reference copy number;
(c) predicting an increased risk of aggressiveness of the prostate tumor when at least 20% of the genomic regions are scored as diseased; and
(d) treating a patient that is predicted to have an increased risk of aggressiveness of the prostate tumor in (c) with a therapy to kill, inhibit, or remove prostate cancer cells.
US Pat. No. 10,968,486

GENE COMPOSITION FOR DETECTING CELL PROLIFERATIVE ABNORMALITY OR GRADING DISEASE DEGREE AND USE THEREOF

Biochain Institute, Inc.,...

1. A composition comprising nucleic acids for detecting the methylation level within at least one target region of RNF180 gene or a fragment thereof, and nucleic acids for detecting the methylation level within at least one target region of Septin9 gene or a fragment thereof, wherein the nucleic acids for detecting the methylation level within the at least one target region of Septin9 gene or a fragment thereof are SEQ ID NOs: 14-16 and the nucleic acids for detecting the methylation level within the at least one target region of RNF180 gene or fragment thereof are SEQ ID NOs: 4, 7, and 8; and wherein SEQ ID NO: 7 is fluorescently labeled.
US Pat. No. 10,966,436

PRODUCTION OF PULSE PROTEIN PRODUCT WITH REDUCED ASTRINGENCY

1. A pulse protein product which is pea or lentil and which has a protein content of at least about 60 wt % (N×6.25) d.b. which has a solubility at 1% protein w/v in water at a pH of about 2 to about 7 of greater than about 50%, as determined by the protein method or the pellet method as calculated from the formulae:Solubility (protein method) (%)=(% protein in supernatant/% protein in initial dispersion)×100  1)
Solubility (pellet method) (%)=(1?(weight dry insoluble pellet material/((weight of 20 ml of dispersion/weight of 50 ml of dispersion)×initial weight dry protein powder)))×100.  2)
US Pat. No. 10,966,949

DIETARY SUPPLEMENTATION TO ACHIEVE OXY-REDOX HOMEOSTASIS AND EPIGENETIC STABILITY

PARTHENOGEN SAGL, Lugano...

1. A composition comprising:a) methyl-tetra-hydrofolate and/or a pharmaceutically acceptable salt thereof in an amount between 100 and 800 ?g of folic acid equivalents;
b) methylcobalamin and/or the pharmaceutically acceptable salts thereof in an amount between 0.5 and 10 ?g of cyanocobalamin equivalents;
c) at least two vitamins B selected among vitamin B2, nicotinamide, vitamin B3 and vitamin B6 and/or the pharmaceutically acceptable salts thereof in an amount between 0.4 ?g and 40 mg;
d) a betaine and/or the pharmaceutically acceptable salts thereof in an amount between 100 and 2000 mg;
e) a chelated zinc compound in an amount between 5 and 50 mg of zinc equivalents; and
f) a cysteine derivative in an amount between 100 and 2000 mg,
wherein the composition does not contain any antioxidant agent.
US Pat. No. 10,968,487

OLIGONUCLEOTIDES AND METHODS FOR DETECTING KRAS AND PIK3CA MUTATIONS

Siemens Healthcare Diagno...

1. A method of detecting KRAS mutations at one or more of codons 12, 13, and 61, comprising the steps of:extracting DNA from a biological sample;
assaying the DNA via kPCR for KRAS mutations at one or more of codons 12, 13, and 61 with at least one set of oligonucleotides, wherein the at least one set of oligonucleotides comprises:
(i) a forward primer of SEQ ID NO: 2, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(ii) a forward primer of SEQ ID NO: 3, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(iii) a forward primer of SEQ ID NO: 4, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(iv) a forward primer of SEQ ID NO: 5, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(v) a forward primer of SEQ ID NO: 6, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(vi) a forward primer of SEQ ID NO: 7, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(vii) a forward primer of SEQ ID NO: 8, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(viii) a forward primer of SEQ ID NO: 9, a reverse primer of SEQ ID NO: 11, and a probe of SEQ ID NO: 10;
(ix) a forward primer of SEQ ID NO: 24, a reverse primer of SEQ ID NO: 25, and a probe of SEQ ID NO: 26; or
(x) a combination thereof;
wherein the kPCR assay is run against a background of wild-type DNA; and
determining a cycle threshold (Ct) cutoff value for the KRAS mutation by comparing Ct signal differences between the mutant DNA and the wild-type DNA.
US Pat. No. 10,968,488

APPLICATION OF SNP (SINGLE NUCLEOTIDE POLYMORPHISM) LOCI OF WHOLE GENOME OF YAK, PRIMER GROUP FOR DETECTION AND KIT

Inst. of Animal Science a...

1. A method of screening a yak to determine its genotype, comprising:obtaining a sample of genetic material from said yak; and
assaying each of the following 16 SNP (Single Nucleotide Polymorphism) loci in the sample to detect genetic markers in said yak:
AX-174702570, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 1;
AX-174961896, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 2;
AX-174407967, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 3;
AX-174402854, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 4;
AX-174929694, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 5;
AX-174547362, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 6;
AX-174734142, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 7;
AX-174706158, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 8;
AX-174783962, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 9;
AX-174627015, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 10;
AX-174928167, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 11;
AX-174555047, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 12;
AX-174845027, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 13;
AX-174891371, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 14;
AX-174570649, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 15; and
AX-174620133, at position 36 of the nucleotide sequence as shown in SEQ ID NO: 16.
US Pat. No. 10,966,438

EXTRUDED ANIMAL FEED WITH GELATIN BINDER AND LOW STARCH CONTENT AND METHOD OF MAKING

PURINA ANIMAL NUTRITION L...

1. An extruded food particle comprising:nutritional food components;
a starch fraction having a concentration of less than about 15 weight percent, the starch being insufficient and unavailable to serve as a binder; and
gelatin present at about 0.2 to 3.0 weight percent of a food particle during extrusion when the extruded food particle has a particle size of less than about ? inch, and gelatin present at about 0.3 to 5 weight percent of the food particle during extrusion when the extruded food particle has a particle size of about ? inch or larger,
wherein the gelatin is substantially distributed throughout the extruded food particle and in a form effective to bind the extruded food particle in a particle form,
wherein the particle has a moisture content of less than about 12 weight percent of the particle, and
wherein the particle has a percent durability of at least approximately 70% as determined by a modified K-state durability test.
US Pat. No. 10,968,489

METHODS AND COMPOSITIONS FOR CHARACTERIZING DRUG RESISTANT BACTERIA FROM FORMALIN-FIXED PARAFFIN-EMBEDDED BIOLOGICAL SAMPLES

AMERICAN MOLECULAR LABORA...

1. A method for detecting within a Helicobacter pylori (H. pylori) sample mutations in a plurality of drug resistance genes, the method comprising:a) identifying PCR primer pairs suitable for producing amplicons comprising regions of each of the genes containing one or more mutations,
b) segregating PCR primer pairs comprising one or more primers that interfere with amplicon generation by another PCR primer pair into separate PCR primer pair pools, wherein each of the separate PCR primer pair pools contains a plurality of PCR primer pairs;
c) generating amplicons from each of the separate PCR primer pair pools and target DNA isolated from the sample;
d) combining all amplicons produced from each of the separate PCR primer pair pools and the target DNA into a sample amplicon pool, adding a unique index sequence to the amplicons within the sample amplicon pool to generate an indexed sample amplicon pool, optionally further combining the indexed sample amplicon pool with one or more differentially indexed sample amplicon pools from different samples, and sequencing all indexed sample amplicons simultaneously; and
e) identifying mutations within the indexed sequenced amplicons from a sample by reference to corresponding wild-type gene sequences,
wherein amplicons diagnostic for at least three different types of drug resistance genes are produced from two PCR reactions in step (c); and
wherein the PCR primer pair pools in step (b) contain:
i) PCR primer pair pool 1 comprising primers SEQ ID NOs. 1-10;
ii) PCR primer pair pool 2 comprising primers SEQ ID NOs. 11-22;
iii) PCR primer pair pool 3 comprising primers SEQ ID NOs. 23-28;
iv) PCR primer pair pool 4 comprising primers SEQ ID NOs. 29-32;
v) PCR primer pair pool 5 comprising primers SEQ ID NOs. 33-38; and
vi) PCR primer pair pool 6 comprising primers SEQ ID NOs. 39-44.
US Pat. No. 10,966,952

CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS

ANAVEX LIFE SCIENCES CORP...

9. A crystalline form of ANAVEX19-144 characterized by the PXRD pattern shown in FIG. 17.
US Pat. No. 10,966,953

COMPOSITIONS COMPRISING A CANNABINOID AND SPILANTHOL

SCICANN THERAPEUTICS INC....

1. A therapeutic composition consisting essentially of synergistically effective amounts of cannabidiol and spilanthol.
US Pat. No. 10,966,441

REFRIGERATION/COLD STORAGE FOOD SAFETY FILTERS

1. A filter for reducing airborne contaminants, airborne moisture, or a combination thereof in a cold storage unit comprising:a packaging comprised of a porous material; and
a mixture contained within the packaging comprising
between about 50-75% w/w diatoms;
between about 20-30% w/w dried hygroscopic plant botanicals;
and between about 10-15% w/w dried antibacterial plant botanicals;
wherein the dried hygroscopic plant botanicals are selected from the group consisting of flax fibers, coconut fibers, oat powder, rye fiber, wheat fiber, bamboo fiber and combinations thereof,
wherein the dried antibacterial plant botanicals are selected from the group consisting of blueberry fiber, cranberry powder, caraway, celery, coriander, cilantro, tree bark, echinacea, fava bean, lemon peel, orange peel, grapefruit peel, turmeric, papaya fiber and combinations thereof;
wherein the mixture contains the diatoms, the hygroscopic plant botanicals and the antibacterial plant botanicals in a weight ratio of 5:2:1;
wherein the porous material of the packaging is an FDA-approved food grade material selected from the group consisting of a flashspun material of high density polyethylene fibers and kraft paper;
wherein the packaging is in the form of a bag or pouch capable of containing the mixture in an interior of the bag or pouch;
wherein the porous material of the packaging allows airborne contaminants and airborne moisture to pass through the porous material while preventing the mixture from leaking out of the porous material of the packaging.
US Pat. No. 10,967,466

LAYERED ASSEMBLIES FOR SUPERALLOY ARTICLE REPAIR

KENNAMETAL INC., Latrobe...

1. A nickel-based superalloy article comprising:a damaged region; and
a nickel-based filler alloy metallurgically bonded to the damaged region, the nickel-based filler alloy having composition of 8-15 wt. % chromium, 7-14 wt. % cobalt, 0.1-5 wt. % molybdenum, 5-11 wt % tungsten, 1-5 wt. % tantalum, 2-7 wt. % aluminum, 0.1-1.5 wt % boron, 0.1-5 wt % titanium, 0-2 wt % hafnium, 0.05-1 wt. % carbon, 0-0.5 wt. % yttrium and the balance nickel, wherein primary carbide and secondary carbide phases are present in the nickel-based filler alloy in a combined amount of 0.5 to 10 vol. %.
US Pat. No. 10,968,492

HPPD-INHIBITOR HERBICIDE TOLERANCE

PIONEER HI-BRED INTERNATI...

1. A method for selectively screening soybean plants for tolerance to one or more herbicides selected from the group consisting of a mesotrione herbicide and an isoxazole herbicide, the method comprising:(a) crossing a first soybean plant with a second soybean plant to form a soybean plant or soybean germ plasm population;
(b) isolating nucleic acids from the soybean plant or soybean germplasm of the population;
(c) detecting in the nucleic acids at least one allele of one or more marker loci associated with tolerance or improved tolerance to the one or more herbicides, wherein the one or more marker loci localize within a chromosome interval selected from the group consisting of:
(i) the chromosomal interval flanked by and including markers S04867-1-A and S03859-1-A on linkage group L
(ii) the chromosomal interval flanked by and including markers S08110-1-Q1 and S08010-1-Q1 on linkage group L;
(iii) the chromosomal interval flanked by and including markers S08117-1-Q1 and S08010-1-Q1 on linkage group L;
(iv) the chromosomal interval flanked by and including markers S08110-1-Q1 and S08105-1-Q1 on linkage group L;
(v) the chromosomal interval flanked by and including markers S08117-1-Q1 and S08105-1-Q1 on linkage group L; and
(vi) the chromosomal interval flanked by and including markers S08113-1-Q1 and S08105-1-Q1 on linkage group L;
(d) selecting the soybean plant or soybean germplasm comprising the at least one allele of one or more marker loci thereby selecting a plant with tolerance or improved tolerance to the one or more herbicides.
US Pat. No. 10,968,237

METHOD FOR CONTINUOUS PRODUCTION OF TETRAALKOXYSILANE

Korea Institute of Scienc...

1. A method for producing tetraalkoxysilane, comprising:reacting a compound represented by Chemical Formula 1 below with an alkali metal to produce a basic catalyst represented by Chemical Formula 2 below; and
mixing the basic catalyst represented by Chemical Formula 2, silicon metal, and an alcohol represented by i-Chemical Formula 3 below to produce tetraalkoxysilane:
Chemical Formula 1
R1O(CHR2CH2O)n—H,
Chemical Formula 2
R1O(CHR2CH2O)n-M, and
Chemical Formula 3
R3OH,
where M is alkali metal,
R1 represents a C1-C5 linear hydrocarbon group or a C3-C5 branched hydrocarbon group,
R2 represents H or a C1-C3 linear hydrocarbon group,
R3 represents a C1-C2 alkyl group, and
n is an integer of 2-3,
wherein the silicon metal is employed in the mixing step after reducing and removing oxides (SiOx) present on the surface thereof by treating with a mixed gas of hydrogen and an inert gas selected from the group consisting of argon, nitrogen, or combinations thereof at a temperature ranging from 400 to 600° C.
US Pat. No. 10,966,443

PHYTOCHEMICAL COMPOSITIONS USED AS DISINFECTANTS AND PRESERVATIVES FOR FOOD

Universidad Autonoma del ...

1. A composition for disinfecting contaminated seeds comprising:(a) 1% Hibiscus sabdariffa L. calyxes extract;
(b) 0.1% acetic acid
(c) 0.1 to 1.0% sodium hypochlorite,wherein the seeds are contaminated with foodborne bacteria selected from the group consisting of salmonella and E. coli O157:H7,wherein the seeds are 70 to 90% germinated, andwherein the composition is administered to the seeds to effectively eliminate the contamination and obtain sprouts without the foodborne bacteria.
US Pat. No. 10,966,956

PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR

1. A method for treating a tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof, wherein the PD-1 antagonist is an anti-PD-1 antibody, and wherein the tumor is selected from the group consisting of breast cancer, colorectal cancer, and kidney cancer.
US Pat. No. 10,968,494

DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS

GEN-PROBE INCORPORATED, ...

12. A method for of determining the presence or absence of a human papillomavirus (HPV) nucleic acid type in group A2 in a sample, comprising the steps of:(a) contacting a sample, said sample suspected of containing a target nucleic acid of an HPV type in group A2, with a combination of amplification oligomers that amplify a target region of said target nucleic acid, wherein
(i) a first amplification oligomer comprises a target-specific sequence and a 5? promoter sequence, wherein the first amplification oligomer target-specific sequence consists of SEQ ID NO:25 or SEQ ID NO:27, or an RNA equivalent thereof; and
(ii) a second amplification oligomer comprises a target-specific sequence consisting of SEQ ID NO:38, or an RNA equivalent thereof;
(b) performing an amplification reaction using the amplification oligomers, wherein if the target nucleic acid of the HPV type in group A2 is present in the sample, an amplification product is produced; and
(c) detecting the amplification product.
US Pat. No. 10,966,444

METHOD FOR FREEZING OLIVE OIL

1. A method for preserving polyphenols when producing and freezing olive oil, comprising:extracting olive oil from olives using a cold extraction method;
immediately following extraction of olive oil using the cold extraction method, collecting the olive oil into a first stainless container, and providing nitrogen gas into the first stainless the container;
storing the olive oil in the first stainless container for 12 hours at a temperature of 27° C.;
gradually transferring the olive oil from the first stainless container into subsequent containers during a series of stages, each of the series of stages being carried out in the presence of nitrogen gas, wherein at each olive oil transfer stage in the series of stages from one subsequent container to another, the temperature of the olive oil is decreased by about 5° C., wherein a total temperature decrease over the series of stages is from 27° C. to 7° C., and wherein the olive oil is stored at the decreased temperature during each of the series of stages for 12 hours;
packaging the olive oil into retail containers following completion of a last stage of the series of stages; and
freezing the olive oil in the retail containers to a temperature of between ?18° C. to ?23° C.
US Pat. No. 10,966,957

METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDAC1) SUBSTANCES

RESEARCH CANCER INSTITUTE...

1. A method for treating a patient having cancer, comprising:administering a predetermined dose of one or more HDACI substances to the patient; and,
subjecting the patient to a hyperbaric pressure environment of substantially pure oxygen;
said predetermined dose, hyperbaric pressure, and the duration of said subjection being selected to have a therapeutic effect on said cancer, wherein the said patient is administered a therapeutic amount of octreotide.
US Pat. No. 10,968,496

RECOMBINANT VIBRIO NATRIEGENS ORGANISMS HAVING A MODIFIED OUTER MEMBRANE

Codex DNA, Inc., San Die...

1. A recombinant Vibrio natriegens organism comprising:a deletion, inactivation, or disruption of the lpxL gene or the lpxM gene,
wherein the organism produces substantially less endotoxin compared to a corresponding organism not comprising the deletion, inactivation, or disruption and cultivated under the same conditions;
wherein the recombinant Vibrio natriegens organism exhibits a growth rate of at least 60% of the growth rate of the corresponding organism when cultivated under the same conditions; and
wherein the organism has an endotoxin level of less than 50 EU/ml of purified lipopolysaccharide.
US Pat. No. 10,966,960

MEDICAL TREATMENT COMPRISING ENTERAL ADMINISTRATION OF EDARAVONE

TREEWAY TW001 B.V., Rott...

1. A method of administering edaravone to a subject in need thereof, comprising:(a) dispersing a pharmaceutical composition comprising edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) into an aqueous liquid to produce a pharmaceutical liquid comprising at least 0.5 grams of the pharmaceutical composition and at least 0.3 g/l of edaravone, followed by
(b) enterally administering the pharmaceutical liquid to a human patient in an amount providing a dose of 30-300 mg edaravone, the pharmaceutical composition comprising:
(i) 2-50 wt. % of edaravone; and
(ii) 3-50 wt. % of water soluble alkalizing agent;
wherein the edaravone in the pharmaceutical composition fully dissolves in a solution when the composition is added to demineralized water of 25° C. in a concentration equivalent to an edaravone concentration of 1.4 g/l, and wherein the pH of the solution at 25° C. is at least 0.5 pH units higher than the pH of a solution having the same edaravone concentration and consisting exclusively of edaravone and demineralized water.
US Pat. No. 10,966,448

FASTING MIMICKING AND ENHANCING DIET FOR TREATING HYPERTENSION AND LIPID DISORDERS

University of Southern Ca...

1. A method for treating a subject with elevated insulin, the method comprising:a) identifying a subject having elevated insulin; and
b) administering a hypocaloric or a fasting mimicking diet (FMD) to the subject to reduce elevated insulin, the hypocaloric or fasting mimicking diet providing less than 30 grams of sugar on day 1, less than 28 grams of protein on day 1, 20-30 grams of monounsaturated fats on day 1, 6-10 grams of polyunsaturated fats on day 1, 2-12 grams of saturated fats on day 1, less than 20 grams of sugar on days 2-5, less than 18 grams of protein on days 2-5, 10-15 grams of monounsaturated fats on days 2-5, 3-5 grams of polyunsaturated fats on days 2-5, and 1-6 grams of saturated fats on days 2-5 wherein a rice-protein based mix is provided as a source of protein, the rice-protein based mix being composed of vitamins, minerals, essential fatty acids and enzymatically processed rice protein from whole sprouted brown rice.
US Pat. No. 10,968,499

FERRITIC STAINLESS STEEL AND PROCESS FOR PRODUCING SAME

JFE STEEL CORPORATION, T...

1. A ferritic stainless steel comprising:a chemical composition consisting of, in mass %,
C: 0.005% to 0.050%,
Si: 0.01% to 1.00%,
Mn: 0.01% to 1.0%,
P: 0.040% or less,
S: 0.010% or less,
Cr: 15.5% to 17.5%,
Ni: 0.01% to 1.0%,
Al: 0.001% to 0.10%, and
N: 0.005% to 0.06%,
and optionally
one or more selected from Cu: 0.01% to 1.0%, Mo: 0.01% to 0.5%, and Co:
0.01% to 0.5%,
and optionally
one or more selected from V: 0.01% to 0.25%, Ti: 0.001% to 0.10%, Nb: 0.001% to 0.05%, Ca: 0.0002% to 0.0020%, Mg: 0.0002% to 0.0050%, B: 0.0002% to 0.0050%, and REM: 0.01% to 0.10%,
with a balance being Fe and incidental impurities;
a microstructure containing ferrite crystal grains which satisfy at least one of a C concentration of 2CC or more and an N concentration of 2CN or more, the ferrite crystal grains having a volume fraction with respect to a whole volume of the microstructure of 5% or more and 50% or less, where CC and CN are respectively C content and N content in the steel in mass %; and
a Vickers hardness of 180 or less.
US Pat. No. 10,966,962

METHOD FOR TREATING NEURODEGENERATIVE DISEASES

THE BOARD OF TRUSTEES OF ...

1. A method of suppressing myeloid-mediated inflammation in a subject diagnosed with a neurodegenerative disease, comprising the step of administering to a subject suffering from a neurodegenerative disease an effective amount of 2-(4-tert-butylphenyl)-1H-benzimidazole, or a solvate or pharmaceutically acceptable salt thereof.
US Pat. No. 10,969,524

DYE MICROENVIRONMENT

Vision Ease, LP, Ramsey,...

1. A method for controlling a characteristic of a photochromic dye comprising:selecting a composition of a first microenvironment immediately surrounding a first photochromic dye to control a characteristic of the first photochromic dye through non-covalent interaction between the first photochromic dye and the first microenvironment;
creating a first particle comprising the first photochromic dye and the microenvironment immediately surrounding the first photochromic dye;
incorporating the first particle within a continuous adhesive host phase having a composition distinct from the composition of the first microenvironment immediately surrounding the first photochromic dye, the host phase being flexible upon curing or complete reaction; and
permanently containing the composition of the first microenvironment and the photochromic dye inside said first particle without being diffused into said adhesive host phase.
US Pat. No. 10,968,245

METHOD FOR PREPARING TRICARBONYL TECHNETIUM-99M INTERMEDIATE

Institute of High Energy ...

1. A method for preparing a technetium-99m tricarbonyl intermediate, comprising reacting at room temperature a manganese carbonyl compound as a carbon monoxide source with pertechnetate and water to obtain the technetium-99m tricarbonyl intermediate, wherein the technetium-99m tricarbonyl intermediate is [99mTc(H2O)3(CO)3]+;wherein the pertechnetate reacts at room temperature with the manganese carbonyl compound and water in the presence of a reducing agent and the manganese carbonyl compound is manganese carbonyl and/or manganese pentacarbonyl halide;
the pertechnetate reacts at room temperature with the manganese carbonyl compound and water in the presence of a reducing agent under UV light irradiation and the manganese carbonyl compound is one or more selected from the group consisting of cyclopentadienyl manganese tricarbonyl, methyl cyclopentadienyl manganese tricarbonyl and cyclopentadienecarboxylic acid manganese tricarbonyl; or
the pertechnetate reacts at room temperature with 1-cyclopentadiene manganese tricarbonyl-N,N,N-trimethylammonium borohydride and water under UV light irradiation.
US Pat. No. 10,966,964

METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION COMPRISING PYRROLO-FUSED SIX-MEMBERED HETEROCYCLIC COMPOUND

Jiangsu Hengrui Medicine ...

1. A method for preparing a pharmaceutical composition, comprising:1) mixing together by weight of the total pharmaceutical composition:
a) 10-20 wt % of 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof,
b) 30-80 wt % of lactose or mannitol;
c) 5-50 wt % of pregelatinized starch;
d) 1-30 wt % of a disintegrant, wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose and crospovidone; and
e) 0.5-5 wt % of a lubricant, wherein the lubricant is at least one selected from the group consisting of magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, and talc to form a mixture;
2) dry granulating the mixture to form dry granules; and
3) tableting the dry granules into tablets or filling the dry granules into capsules,
wherein the 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or the pharmaceutically acceptable salt thereof has a particle size distribution range d(0.9) of less than 60 ?m.
US Pat. No. 10,966,965

GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION

30. A method for reducing a risk of suicide in a patient diagnosed as being at risk of suicide comprising;providing a first treatment of gaboxadol, or pharmaceutically acceptable salt thereof, to a patient in need thereof in an amount sufficient to reduce the risk of suicide, and, providing at least one additional treatment of gaboxadol, or pharmaceutically acceptable salt thereof, after a wash-out period of at least 48 hours after the first treatment.
US Pat. No. 10,968,503

NON-ORIENTED ELECTRICAL STEEL SHEET

NIPPON STEEL CORPORATION,...

1. A non-oriented electrical steel sheet, comprising a chemical composition represented by:in mass %,
C: 0.0030% or less;
Si: 2.00% to 4.00%;
Al: 0.10% to 3.00%;
Mn: 0.10% to 2.00%;
S: 0.0030% or less;
one kind or more selected from a group consisting of Mg, Sr, Ba, Ce, La, Nd, Pr, Zn, and Cd: 0.0003% or more and less than 0.0015% in total;
a parameter Q represented by an equation 1 when the Si content (mass %) is set to [Si], the Al content (mass %) is set to [Al], and the Mn content (mass %) is set to [Mn]: 2.00 or more;
Sn: 0.00% to 0.40%;
Cu: 0.0% to 1.0%;
Cr: 0.0% to 10.0%; and
a balance: Fe and impurities, wherein:
the total mass of S contained in sulfides or oxysulfides of Mg, Sr, Ba, Ce, La, Nd, Pr, Zn, or Cd is 10% or more of the total mass of S contained in the non-oriented electrical steel sheet;
a {100} crystal orientation intensity is 3.0 or more;
a thickness is 0.15 mm to 0.30 mm; and
an average crystal grain diameter is 65 ?m to 100 ?m,
Q=[Si]+2[Al]?[Mn]  (Equation 1).
US Pat. No. 10,973,118

FLEXIBLE CONDUCTIVE FILM, ITS MANUFACTURING METHOD, FLEXIBLE TOUCH SCREEN AND FLEXIBLE DISPLAY PANEL

BOE TECHNOLOGY GROUP CO.,...

1. A manufacturing method of a flexible conductive film, the flexible conductive film comprising a solidified polyimide varnish film and a first conductive metal pattern and a second conductive metal pattern embedded in the solidified polyimide varnish film, the manufacturing method comprising:providing a first substrate;
applying a first conductive metal ink on the first substrate and forming the first conductive metal pattern;
providing a second substrate;
applying a second conductive metal ink on the second substrate and forming the second conductive metal pattern insulated from and intersected with the first conductive metal pattern;
applying a polyimide varnish film on a first surface of the first substrate having the first conductive metal pattern and a second surface of the second substrate having the second conductive metal pattern and facing the first surface of the first substrate;
wherein the first conductive metal pattern has a thickness rammed from about 1 ?m to about 10 ?m, the second conductive metal pattern has a thickness ranged from about 1 ?m to about 10 ?m, and the polymide varnish film has a thickness ranged from 50 ?m to 250 ?m to allow the first conductive metal pattern and the second conductive metal pattern to be completely embedded in the polymide varnish film;
soaking the first substrate and the second substrate in deionized water after the polyimide varnish film has been solidified; and
detaching the solidified polyimide varnish film and the first conductive metal pattern and the second conductive metal pattern from the first substrate to obtain the flexible conductive film.
US Pat. No. 10,966,966

METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS

Deciphera Pharmaceuticals...

1. A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient a 150 mg daily dose of ripretinib, wherein the patient's tumor has progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib, and wherein the patient achieves 6 months of progression free survival, as determined by mRECIST 1.1, after at least 28 days of the daily ripretinib administration.
US Pat. No. 10,968,248

TRINUCLEOTIDE MRNA CAP ANALOGS

Arcturus, Inc., San Dieg...

1. A compound of formula m7G(5?)p3(5?)N1pN2, whereinm7G is a ribonucleotide consisting of N7-methylguanine and a ribose or a modified ribose, wherein one or both of the 2? or 3? carbons of the modified ribose has a fluoro or a C1-C6 alkoxy substituent;
(5?)p3(5?) is a 5? to 5? triphosphate linkage, wherein the triphosphate linkage may be substituted with one or more phosphorothioate groups;
N1 is a ribonucleotide comprising a seco (UNA) ribose optionally substituted at the 2? or 3? carbons with one or more fluoro or C1-C6 alkoxy substituents, and a base selected from the group consisting of adenine, uridine, guanine, cytosine, N6-methyladenine, N1-methyladenine, pseudouracil, N1-methylpseudouracil, 5-iodouracil, 4-thiouracil, 2-thiouracil, 5-methyluracil, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N4-methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N1-methylguanine, O6-methylguanine, N2-methylguanine (m2G), N2,N2-dimethylguanine (m2,2G), N2,N7-dimethylguanine (m2,7G), and isoguanine; and
N2 is a ribonucleotide consisting of (i) a base selected from the group consisting of adenine, uridine, guanine, cytosine, N6-methyladenine, N1-methyladenine, pseudouruacil, N1-methylpseudouracil, 5-iodouracil, 4-thiouracil, 2-thiouracil, 5-methyluracil, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N4-methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N1-methylguanine, O6-methylguanine, N2-methylguanine (m2G), N2,N2-dimethylguanine (m2,2G), N2,N7-dimethylguanine (m2,7G), and isoguanine; and (ii) a ribose moiety comprising a ribose or a modified ribose, wherein one or both of the 2? or 3? carbons of the modified ribose has a fluoro or a C1-C6 alkoxy substituent;
wherein the m7G ribonucleotide is linked at its 5?-OH to the triphosphate bridge, the triphosphate bridge is linked to a 5?-OH of the N1 ribonucleotide, the N1 nucleotide is linked via its 3?-OH to a phosphate, p, and the phosphate is linked to a 5?-OH of the N2 ribonucleotide;
or a salt or solvated form thereof.
US Pat. No. 10,968,504

AUSTENITIC STAINLESS ALLOY

Sandvik Intellectual Prop...

1. An austenitic stainless alloy consisting of in weight %:C less than 0.03;
Si more than 0.1 to less than 1.0;
Mn 0.6 to 1.1;
Cr 26.0 to 30.0;
Ni 34.0 to 37.0;
Mo 6.3 to 7.1;
N 0.25 to 0.36;
P less than or equal to 0.04;
S less than or equal to 0.03;
Cu 0.001 to 0.4;
one or more elements of the group of Al, V, Nb, Ti, O, Zr, Hf, Ta, Mg, Pb, Co, Bi, Ca, La, Ce, Y and B in a total content of less than or equal to 1.0; and
a balance of Fe and unavoidable impurities,
wherein the austenitic stainless alloy has a yield strength (Rp0 2) of 351 MPa to 427 MPa, and
wherein the austenitic stainless alloy has a critical pitting temperature of greater than 108° C., conducted per ASTM G150 with 3M MgCl2 and ground sample.
US Pat. No. 10,968,507

SPRAYED COATING, METHOD FOR MANUFACTURING SPRAYED COATING, SPRAYED MEMBER AND SPRAYING MATERIAL

SHIN-ETSU CHEMICAL CO., L...

1. A sprayed coating having a multilayer structure comprising a lower layer made of a sprayed coating comprising a rare earth oxide, and a surface layer made of another sprayed coating comprising a rare earth fluoride and/or a rare earth oxyfluoride, whereinsaid sprayed coating having the multilayer structure has a volume resistivity at 23° C. and a volume resistivity at 200° C., the volume resistivity at 23° C. being 1×109 to 1×1012 ?·cm, and a temperature index of the volume resistivities defined by the ratio of the volume resistivity at 200° C. to the volume resistivity at 23° C. being 0.1 to 10.
US Pat. No. 10,968,508

METHOD OF FABRICATING HYDROPHILIC-HYDROPHOBIC TRANSFORMABLE COMPOSITE FILM

TATUNG UNIVERSITY, Taipe...

1. A method of fabricating a hydrophilic-hydrophobic transformable composite film, comprising:(A) forming a silicon layer, by a sputtering process, on an iron-containing substrate;
(B) spin-coating a titanium-containing sol-gel film on the said silicon layer for twice or more; and
(C) heating the iron-containing substrate with the silicon containing layer and the titanium-containing sol-gel film thereon after the step (B) such that the titanium-containing sol-gel film is formed into a porous film,
wherein the iron-containing substrate is made of interstitials free (IF) steel, and the porous film is formed of anatase titanium oxide; and
wherein sputtering conditions of the sputtering process are as follows:
the distance between a target and the iron-containing substrate is 5 cm,
the processing time is 20 minutes,
the chamber bottom pressure is 3.5×10?5 torr,
the working pressure is 8.5×10?3 torr,
the argon flow rate is 30 sccm,
and the operating power is 125 W.
US Pat. No. 10,966,459

ELECTRICALLY HEATED SMOKING SYSTEM

Altria Client Services LL...

1. An electrically heated smoking system comprising:a housing configured to receive an aerosol-forming substrate;
a heater disposed within the housing, the heater including a conductive ceramic material and platinum deposited on a carrier material that is configured to be positioned in contact with the aerosol-forming substrate to heat the aerosol-forming substrate, the conductive ceramic material including molybdenum disilicide;
electrical hardware disposed within the housing and connected to the heater, the electrical hardware configured to control the heater and to store parameters associated with an operation of the heater in memory; and
an interface configured to connect the electrical hardware to a host device, the interface configured to facilitate a transmission of at least one of data and power between the electrical hardware and the host device, the interface being in a form of a USB socket.
US Pat. No. 10,966,971

PHARMACEUTICAL COMPOSITIONS OF POMALIDOMIDE

Natco Pharma Limited, Hy...

1. A pharmaceutical composition in the form of a capsule comprising: i) Pomalidomide; ii) binder or filler at an amount of 80% to 89%, wherein the binder or filler is a mixture of mannitol and pregelatinized starch; iii) a disintegrant selected from croscarmellose sodium, sodium starch glycolate, and crosslinked polyvinylpyrrolidone; and iv) a lubricant selected from sodium stearyl fumarate, stearic acid, magnesium stearate, and talc.
US Pat. No. 10,968,253

METHODS AND PRODUCTS FOR GENETIC ENGINEERING

INSTITUT NATIONAL DE LA S...

1. A retrovirus-derived particle comprising one or more Cas protein(s) wherein the one or more Cas protein is contained within an inside of said particle as a fusion protein between (i) a viral structural protein and (ii) the one or more Cas protein(s), wherein the retrovirus-derived particle is devoid of any encoding nucleic acid, and wherein the one or more Cas protein(s) is complexed with one or more CRISPR-Cas system guide RNA(s).
US Pat. No. 10,966,972

TREATING OF SIDE-EFFECTS RESULTING FROM CHEMODENERVATION

DELNOVA, Inc., Highland ...

1. A method of restoring neuromuscular transmission by locally administering an effective dose of a composition comprising an anticholinesterase to a non-responsive muscle, wherein the non-responsive muscle has been previously exposed to botulinum toxin, wherein the composition is targeted locally and administered directly to the non-responsive muscle.
US Pat. No. 10,968,254

TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS

1. An isolated non-naturally occurring recombinant human immunodeficiency virus (HIV) envelope (Env) protein wherein the amino acid at position 658 is chosen from the group consisting of Val, Ile, Phe, Met, and Ala; wherein the numbering of the positions is according to the numbering in gp160 of HIV-1 isolate HXB2 as shown in SEQ ID NO: 1.
US Pat. No. 10,968,255

COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE CH235 LINEAGE ANTIBODIES

Duke University, Durham,...

1. A recombinant HIV-1 envelope polypeptide comprising all the consecutive amino acids after the signal peptide in HIV-1 envelope CH505TFchim.6R.SOSIP.664v4.1 (SEQ ID NO:260), CH505M5chim.6R.SOSIP.664v4.1 (SEQ ID NO:242), CH505M11chim.6R.SOSIP.664v4.1 (SEQ ID NO:244), CH505w20.14chim.6R.SOSIP.664v4.1 (SEQ ID NO:254), CH505w30.20.chim.6R.SOSIP.664v4.1 (SEQ ID NO:258), CH505w30.12chim.6R.SOSIP.664v4.1 (SEQ ID NO:256), or CH505w136.B18chim.6R.SOSIP.664v4.1 (SEQ ID NO:252).
US Pat. No. 10,966,974

BUPROPION AS A MODULATOR OF DRUG ACTIVITY

ANTECIP BIOVENTURES II LL...

1. A method of treating depression, comprising orally administering: bupropion, at a daily dose that is about 150 mg to about 250 mg, and dextromethorphan, at a daily dose that is about 60 mg to about 110 mg, to a human being in need thereof for at least 8 consecutive days, wherein the bupropion and the dextromethorphan are administered in a dosage form containing both the bupropion and the dextromethorphan, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form; wherein the dextromethorphan is formulated for immediate release and the bupropion is formulated for sustained release; and wherein orally administering the dosage form is more effective in treating depression than orally administering the same amount of the bupropion alone for 8 consecutive days.
US Pat. No. 10,968,256

OPTOGENETIC SYSTEM BASED ON BACTERIAL PHYTOCHROME CONTROLLABLE WITH NEAR INFRA-RED LIGHT

Albert Einstein College o...

1. A method for inducing interaction of a first protein with a second protein in a system, the method comprising providing a system comprising(a) a first fusion protein comprising (i) a protein having the sequence of a Rhodopseudomonas palustris bacterial phytochrome RpBphP1 (BphP1) and (ii) the first protein, and
(b) a second fusion protein comprising (i) a protein having the sequence of a Rhodopseudomonas palustris transcriptional repressor RpPpsR2 (PpsR2) or a non-dimerizing variant thereof, wherein the non-dimerizing variant of PpsR2 has an amino acid sequence of SEQ ID NO:3 and (ii) the second protein, and
(c) an amount of biliverdin; and irradiating the system with near infrared light sufficient to induce interaction of a Rhodopseudomonas palustris BphP1 with a Rhodopseudomonas palustris PpsR2 or a non-dimerizing variant thereof, wherein the non-dimerizing variant of PpsR2 has an amino acid sequence of SEQ ID NO:3.
US Pat. No. 10,968,512

CVD COMPOSITE REFRACTORY COATINGS AND APPLICATIONS THEREOF

KENNAMETAL INC., Latrobe...

1. A coated article comprising:a substrate; and
a coating deposited by chemical vapor deposition (CVD) adhered to the substrate, the coating comprising an inner refractory layer comprising M1-xAlxN wherein x?0.7 and M is titanium, chromium or zirconium and an outer multiphase refractory layer comprising an alumina phase and an oxide phase dispersed uniformly or heterogeneously in the alumina phase, the oxide phase comprising zirconia primarily exhibiting monoclinic crystalline structure, wherein the M1-xAlxN has less than 15 weight percent hexagonal phase.
US Pat. No. 10,968,257

TARGET RECOGNITION MOTIFS AND USES THEREOF

The Broad Institute, Inc....

1. An engineered protein or polypeptide comprising one or more engineered, heterologous Photorhabdus tandem repeat protein target recognition sequence (TRS) motifs.
US Pat. No. 10,966,976

METHODS FOR INDUCING AN IMMUNE RESPONSE BY INHIBITION OF NONSENSE MEDIATED DECAY

MOONSHOT PHARMA LLC, New...

1. A method of treating colon cancer in an individual in need thereof comprising administering to the individual an effective amount of a composition comprising a nonsense mediated decay inhibitor compound selected from NMDI 14, NMDI 9, NMDI 25, and combination thereof, and a composition comprising an inhibitor of an immune checkpoint molecule selected from CTLA-4, PD-1, and combination thereof.
US Pat. No. 10,968,258

STREPTOCOCCUS SUIS VACCINES TO PROTECT AGAINST REPRODUCTIVE, NURSERY-AGE, AND GROWING PIG DISEASES AND METHODS OF MAKING AND USE THEREOF

BOEHRINGER INGELHEIM ANIM...

1. An immunogenic composition that elicits an immunogenic response in an animal against Streptococcus suis (S. suis) infection comprising:a) a S. suis polynucleotide comprising the sequence of SEQ ID NO: 31; or
b) a S. suis polynucleotide encoding a polypeptide comprising the sequence of SEQ ID NO: 32;
and wherein the immunogenic composition further comprises a pharmaceutically or veterinary acceptable vehicle, diluent, excipient or adjuvant.
US Pat. No. 10,966,978

DOSE AND REGIMEN FOR HDM2-P53 INTERACTION INHIBITORS

Novartis AG, Basel (CH)

1. A method for treating cancer in patients in need thereof which comprises administering an effective amount of an HDM2-p53 interaction inhibitor which is HDM201,wherein a daily dose of the inhibitor is administered on two different administration days within a treatment cycle,
wherein the first administration day and second administration day are interrupted by a short administration-free period, and the second administration day of the first or earlier treatment cycle and the first administration of the following cycle are interrupted by a long administration-free period,
wherein the short administration-free period is composed of from 4 to 8 days, and the long administration-free period is composed of from 13 to 27 days, and
wherein the treatment is composed of at least 2 treatment cycles.
US Pat. No. 10,968,260

CURCUMIN-PEPTIDE CONJUGATES AND FORMULATIONS THEREOF

HAUS BIOCEUTICALS, INC., ...

1. A pharmaceutical formulation with increased curcumin bioavailability comprising:a curcumin conjugated to a whey protein isolate (WPI) to form a curcuminoid-peptide complex with a curcumin to peptide ratio of 1:1 w/w (mg:g), 10:1 w/w (mg:g), 25:1 w/w (mg:g), or 50:1 w/w (mg:g) disposed in a pharmaceutically acceptable excipient, diluent, or carrier;
wherein the curcuminoid-peptide complex has increased curcumin bioavailability compared to curcumin alone.
US Pat. No. 10,966,979

AMORPHOUS SOLID DISPERSION OF AN ORALLY AVAILABLE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONIST

Sandoz AG, Basel (CH)

1. A solid dispersion comprising amorphous Elagolix sodium and at least one silicon-based inorganic compound, wherein the silicon-based inorganic compound is a material having a BET specific surface area of at least 1 m2/g, and characterized in that the solid dispersion has a powder X-ray diffractogram comprising no reflection in the range of from 2 to 40° 2-Theta, when measured at a temperature in the range of from 20 to 30° C. with Cu-Kalpha1,2 radiation having a wavelength of 0.15419 nm.
US Pat. No. 10,968,261

METHODS AND COMPOSITIONS FOR GENOME ENGINEERING

Sangamo Therapeutics, Inc...


US Pat. No. 10,968,517

CLEANING METHOD, METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, SUBSTRATE PROCESSING APPARATUS, AND RECORDING MEDIUM

KOKUSAI ELECTRIC CORPORAT...

1. A cleaning method, comprising:supplying a hydrogen fluoride gas into a process vessel, in which a process of forming a SiOC film on a substrate has been performed and a deposit containing SiOC has been adhered to an interior of the process vessel in the process of forming the SiOC film, to remove the deposit,
wherein a quartz member is provided in the process vessel, and
wherein the act of supplying the hydrogen fluoride gas includes setting an internal temperature of the process vessel to 100 degrees C. or higher and 400 degrees C. or lower.
US Pat. No. 10,966,980

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES

Pfizer Inc., New York, N...

1. A compound selected from the group consisting of:[2,2,2-Trifluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}ethanesulfonamide;]
N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide;
2-Methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}propane-1-sulfonamide;
cis-3-(Cyanomethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclo-butanesulfonamide;
trans-3-(Cyanomethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclo-butanesulfonamide;
[N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-1-oxetan-3-ylmethane-sulfonamide;]
cis-3-(Cyanomethyl)-3-methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}cyclobutanesulfonamide;
trans-3-(Cyanomethyl)-3-methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}cyclobutanesulfonamide;
3-(1-Hydroxy-1-methylethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}benzenesulfonamide;
N-{(1S,3R)-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclopentyl}propane-1-sulfonamide;
3,3-Difluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclobutane-sulfonamide;
N-(2-Cyanoethyl)-N-methyl-N?-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}sulfamide;
N-{cis-3-[(Butylsulfonyl)methyl]cyclobutyl}-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-(trans-3-((propylsulfonyl)methyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(2-Cyclopropylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-[cis-3-({[(3,3-Difluorocyclobutyl)methyl]sulfonyl}-methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
(1R, 3R)-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfon-yl]cyclopentane-carbonitrile;
(1S, 3S)-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfon-yl]cyclopentane-carbonitrile;
N-(cis-3-{[(3-Chloro-4-fluorophenyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
[(1S,2S)-trans-2-(cyanomethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}cyclopropanesulfonamide;
(1R,2R)-trans-2-(cyanomethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}cyclopropanesulfonamide]
3-Cyano-3-methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}azet-idine-1-sulfonamide;
cis-3-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclopentanesulfonamide;
trans-3-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclopentane-sulfonamide;
1-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)-sulfonyl]azetidine-3-carbonitrile;
cis-3-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-cyclobutanesulfonamide;
trans-3-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclobutane-sulfonamide;
cis-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-butanecarbonitrile;
trans-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-butanecarbonitrile;
3-Methyl-1-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfon-yl]azetidine-3-carbonitrile;
(1R,5R)-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)-sulfonyl]-3-azabicyclo[3.1.0]hexane-1-carbonitrile;
cis-3-(Difluoromethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclo-butane-sulfonamide;
trans-3-(Difluoromethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclo-butanesulfonamide;
cis-1-(3-Cyano-1-methylcyclobutyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}methanesulfonamide;
trans-1-(3-Cyano-1-methylcyclobutyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}-methanesulfonamide;
cis-3-Fluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}cyclo-butanesulfonamide;
trans-3-Fluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclo-butyl}cyclobutane-sulfonamide;
cis-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-butanecarbonitrile;
trans-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-butanecarbonitrile;
N-Methyl-N-((1S,3S)-3-(((3,3,3-trifluoropropyl)sulfonyl)methyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-[cis-3-({[3-(trifluoromethyl)pyrrolidin-1-yl]sulfonyl}methyl)cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-[cis-3-({[3-(Difluoromethyl)pyrrolidin-1-yl]sulfonyl}methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-pentanecarbonitrile;
N-{cis-3-[(Benzylsulfonyl)methyl]cyclobutyl}-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
1-methyl-3-{[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfon-yl]methyl}cyclobutanecarbonitrile;
N-[cis-3-({[3-(Difluoromethyl)cyclobutyl]sulfonyl}methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
2-methyl-1-{3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfon-yl]azetidin-1-yl}propan-1-one;
(1R,3R)-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-pentanecarbonitrile;
N-Methyl-N-{cis-3-[(2-oxa-6-azaspiro[3.3]hept-6-ylsulfonyl)methyl]cyclobutyl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
(1R,3S)-3-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclo-pentanecarbonitrile;
N-Methyl-N-{cis-3-[(pentan-3-ylsulfonyl)methyl]cyclobutyl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(3-Methoxypropyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(Cyclohexylmethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(3-Fluoropropyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-(cis-3-{[(3-methylbutyl)sulfonyl]methyl}cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(2-Ethylbutyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(cis-3-{[(2-Cyclopentylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-(cis-3-{[(2-methylbutyl)sulfonyl]methyl}cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-(Bicyclo[1.1.1]pent-1-yl)-N-methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide;
N-Methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-N-(pentan-2-yl)methanesulfonamide;
N-Butyl-N-methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methane-sulfonamide;
N-(2-Methoxyethyl)-N-methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide;
N-Ethyl-N-methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide;
N-Cyclobutyl-N-methyl-1-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}meth-anesulfonamide;
2,5-Anhydro-1,3,4-trideoxy-3-{methyl[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]amino}-L-threo-pentitol;
N-[cis-3-({[(3,3-Difluoro-1-methylcyclobutyl)methyl]sulfonyl}methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-(cis-3-{[(4,4,4-trifluorobutyl)sulfonyl]methyl}cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
N-Methyl-N-(cis-3-{[(3,3,3-Trifluoropropyl)sulfonyl]methyl}cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
or,
a pharmaceutically acceptable salt thereof.
US Pat. No. 10,968,262

METHODS OF INCREASING SARCOLEMMAL UTROPHIN

ACCELERON PHARMA INC., C...

1. A method for increasing sarcolemmal utrophin in a patient in need thereof, the method comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof that binds to ActRIIB, wherein the patient has a muscle disorder, and wherein the patient has elevated levels of serum CK-MM marker for muscle degeneration.
US Pat. No. 10,966,981

FATTY ACID SYNTHASE INHIBITORS

Duke University, Durham,...

1. A method of inhibiting Fatty Acid Synthase (FASN) with a FASN inhibitor that binds to the FASN purine-binding cofactor domain, the method comprising contacting cells that express FASN with an inhibitor that binds to the FASN purine-binding cofactor domain.
US Pat. No. 10,966,982

STABLE PHARMACEUTICAL FORMULATIONS OF PEMETREXED

Cipla Limited, Mumbai (I...

1. A long term storage multi-dose ready-to-dilute or ready-to-use pharmaceutical liquid formulation comprising: a) pemetrexed or a pharmaceutically acceptable salt thereof; b) an antioxidant; c) a preservative; d) a buffering agent; and e) a pharmaceutically acceptable fluid, wherein the formulation when stored for six months in a sealed, sterile vial at 25° C./60% RH and 40° C./75% RH contains no more than 1.0% total impurity as measured by HPLC, wherein the preservative comprises benzyl alcohol in an amount from about 3 mg/mL to about 25 mg/mL of the formulation.
US Pat. No. 10,968,520

TREATMENT LIQUID FOR BLACK TRIVALENT CHROMIUM CONVERSION COATING, TRIVALENT CHROMIUM-CONTAINING WATER-SOLUBLE LIQUID FOR FINISHING TREATMENT, AND TREATMENT METHOD OF METAL SUBSTRATE

Nippon Hyomen Kagaku Kabu...

1. A treatment liquid for a black trivalent chromium conversion coating on the surface of a metal substrate, wherein the treatment liquid consists of:one or more organic sulfur compounds;
nitrate ions; and
a thermal reaction product obtained by reacting a trivalent chromium compound with an organic acid or organic acid salt at a temperature of 80° C. or higher and lower than the boiling point,
wherein the treatment liquid is free of a cobalt compound.
US Pat. No. 10,966,983

COMPOSITION FOR EXTERNAL USE

OTSUKA PHARMACEUTICAL CO....

1. A composition for external application to human skin comprising:Component (A): an effective amount of essential oil extract comprising a mixture of star anise oil, Scotch pine oil, and Lavandula hybrida oil for increasing IGF-1 secretion,
Component (B): an effective amount of at least one member selected from the group consisting of adenosine monophosphates and salts thereof for increasing IGF-1 secretion, and
Component (C): at least one member selected from the group consisting of an antiseptic, a humectant, an antioxidant and a sequestering agent;
wherein the composition is in a form selected from the group consisting of an emulsion, a cream, a sheet, a lipstick, a lotion, and a sunscreen; and
wherein Component (A) is present in an amount from about 0.0001 to 25 wt %, and Component (B) is present in an amount from about 0.1 to 10 wt % of the composition.
US Pat. No. 10,968,266

GIP PEPTIDE ANALOGUES

UNIVERSITY OF COPENHAGEN,...

1. A method of inhibiting or reducing one or more of: i) gastric inhibitory polypeptide (GIP)-induced glucagon secretion, ii) GIP-induced insulin secretion, iii) GIP-induced somatostatin secretion, iv) GIP-induced glucose uptake, v) GIP-induced fatty acid synthesis and/or fatty acid incorporation, vi) high or increased expression or activity of a GIPR, vii) post-prandial GIP release, viii) serum levels of free fatty acids and/or triglycerides, and ix) GIP-induced reduction of bone resorption,said method comprising one or more steps of administering to an individual in need thereof a peptide selected from the group consisting of:
a peptide consisting of 28 contiguous amino acids of amino acid sequence EGTFISDYSIAMXoaXobIX1QQDFVNWLLAQX2 (GIP3-30; SEQ ID NO: 74):
a peptide consisting of 26 contiguous amino acids of amino acid sequence TFISDYSIAMXoaXobIX1QQDFVNWLLAQX2 (GIP5-30; SEQ ID NO: 76), wherein Xoa is selected from the group consisting of D, E,
Xob is selected from the group consisting of K, A, H, R,
X1 is selected from the group consisting of H, R, A, K, F, Y and
X2 is selected from the group consisting of K, R, H, A; and
a variant of any one of the above peptides, wherein the amino acid sequence of the variant differs from SEQ ID NO: 74 or SEQ ID NO: 76, only in that the amino acid sequence of the variant comprises one or two amino acid substitutions, wherein said substitutions are selected from the group consisting of: i) substitution of an amino acid having a polar side chain for a different amino acid having a polar side chain wherein amino acids having a polar side chain are Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys; ii) substitution of an amino acid having a non-polar side chain for a different amino acid having a non-polar side chain wherein amino acids having a non-polar side chain are Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met; iii) substitution of an amino acid having an aliphatic side chain for a different amino acid having an aliphatic side chain wherein amino acids having a aliphatic side chain are Gly, Ala Val, Leu, and Ile; iv) substitution of an amino acid having a cyclic side chain for a different amino acid having a cyclic side chain wherein amino acids having a cyclic side chain are Phe, Tyr, Trp, His, and Pro; v) substitution of an amino acid having an aromatic side chain for a different amino acid having an aromatic side chain wherein amino acids having an aromatic side chain are Phe, Tyr, and Trp; vi) substitution of an amino acid having an acidic side chain for a different amino acid having an acidic side chain wherein amino acids having an acidic side chain are Asp, and Glu; vii) substitution of an amino acid having a basic side chain for a different amino acid having a basic side chain wherein amino acids having a basic side chain are Lys, Arg, and His; viii) substitution of an amino acid having an amide side chain for a different amino acid having an amide side chain wherein amino acids having an amide side chain are Asn, and Gln; ix) substitution of an amino acid having a hydroxy side chain for a different amino acid having a hydroxy side chain wherein amino acids having a hydroxy side chain are Ser, and Thr; x) substitution of an amino acid having a sulphur-containing side chain for a different amino acid having a sulphur-containing side chain wherein amino acids having a sulphur-containing side chain are Cys, and Met; xi) substitution of a neutral, weakly hydrophobic amino acid for a different neutral, weakly hydrophobic amino acid wherein neutral, weakly hydrophobic amino acids are Pro, Ala, Gly, Ser, and Thr; xii) substitution of a hydrophilic, acidic amino acid for a different hydrophilic, acidic amino acid wherein hydrophilic, acidic amino acids are Gln, Asn, Glu, and Asp, and xiii) substitution of a hydrophobic amino acid for a different hydrophobic amino acid wherein hydrophobic amino acids are Leu, Ile, and Val; wherein said peptide or variant thereof is an antagonist of a GIP receptor (GIPR).
US Pat. No. 10,966,985

MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS

Array BioPharma Inc., Bo...

1. A method for treating a ROS1-associated cancer in a subject in need thereof, wherein the cancer has developed resistance to a first ROS1 inhibitor, and wherein the cancer has been identified as having one or more ROS1 inhibitor resistance mutations, the method comprising administering(6R,15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one;or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,968,267

SERUM ALBUMIN-20K GROWTH HORMONE FUSION PROTEIN

JCR PHARMACEUTICALS CO., ...

1. A fusion protein having growth-promoting activity, and comprising a human serum albumin and a 20K human growth hormone,wherein the human serum albumin comprises the amino acid sequence set forth as SEQ ID NO:2, of which the tyrosine residue occurring at position 319 from the N-terminus is substituted by any amino acid residue except proline residue, and the alanine residue occurring at position 320 from the N-terminus is substituted by threonine or serine.
US Pat. No. 10,968,268

HUMANIZED ANTI-PACAP ANTIBODIES

1. A humanized anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide having at least 90% identity to SEQ ID NO: 962 and a light chain variable region polypeptide having at least 90% identity to SEQ ID NO: 982,wherein said heavy chain variable region comprises the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 964, the heavy chain CDR2 polypeptide of SEQ ID NO: 966, and the heavy chain CDR3 polypeptide of SEQ ID NO: 968, and
said light chain variable region comprises the light chain CDR1 polypeptide of SEQ ID NO: 984, the light chain CDR2 polypeptide of SEQ ID NO: 986, and the light chain CDR3 polypeptide of SEQ ID NO: 988.
US Pat. No. 10,968,269

MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE

Agilent Technologies, Inc...

1. An isolated MHC multimer comprising (a-b-P)n, wherein n>1 and P is a peptide derived from a Borrelia Decorin Binding Protein A,wherein a is at least the extracellular portion of an HLA*02 heavy chain and b is ?2 microglobulin,
wherein a and b together form a functional MHC complex encoded by an HLA-A*02 allele, whereto the peptide P is bound, forming a MHC peptide complex,
wherein the HLA*02 allele is selected from the group consisting of HLA-A*0201, HLA-A*0202, HLA-A*0203, HLA-A*0211, and HLA-A*0216,
wherein each MHC peptide complex of said MHC multimer is associated with one or more multimerization domains, with the proviso that the one or more multimerization domains is not a cell, and
wherein in each MHC peptide complex, the sequence of P is selected from the group consisting of SEQ ID NOS: 5751 (GIYDLILNA), 5655 (TLLASLLAA), and 5767 (GMQGMKQAV).
US Pat. No. 10,966,988

METHOD FOR SMOKING CESSATION

CALISTA CAPITAL, LLC, Ne...

1. A method of treating a subject for smoking cessation comprising periodically administering to the subject a pharmaceutically effective amount of cefdinir to treat the subject.
US Pat. No. 10,968,270

ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)

VISTERRA, INC., Waltham,...

1. An anti-A PRoliferation Inducing Ligand (APRIL) antibody molecule, comprising:(i) a heavy chain variable region (VH), wherein the heavy chain variable region comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises:
an HCDR1 comprising the amino acid sequence of G-Y-T-F-T-D-Y (SEQ ID NO: 11);
an HCDR2 comprising the amino acid sequence of Y-P-L-R-G-S(SEQ ID NO: 12); and
an HCDR3 comprising the amino acid sequence of H-G-A-Y-Y-S-N-A-F-D-Y (SEQ ID NO: 13), and
(ii) a light chain variable region (VL), wherein the light chain variable region comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises:
an LCDR1 comprising the amino acid sequence of X1-X2-S-X4S-V-D-N-D-G-I-R-F-X14-H (SEQ ID NO: 327), wherein X1 is R or K; X2 is A or S; X4 is E or Q; and X14 is M or L;
an LCDR2 comprising the amino acid sequence of R-A-S-X4-X5-X6-X7 (SEQ ID NO: 328), wherein X4 is N or T; X5 is L or R; X6 is E or A; and X7 is S or T; and
an LCDR3 comprising the amino acid sequence of Q-Q-S-N-K-D-P-Y-T (SEQ ID NO: 16).
US Pat. No. 10,966,989

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING MENTAL, BEHAVIORAL, COGNITIVE DISORDERS

LA PharmaTech Inc., Blac...

1. A pharmaceutical composition, comprising:about 10 mg to about 50 mg of azelastine or of a pharmaceutically acceptable salt of azelastine;
memantine or a pharmaceutically acceptable salt of memantine; and
one or more pharmaceutically acceptable excipients.
US Pat. No. 10,968,271

POLYPEPTIDES AGAINST IL-23

Ablynx N.V., Ghent-Zwijn...

1. Polypeptide comprising an amino acid sequence that is chosen from the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3.
US Pat. No. 10,969,039

MULTILAYERED FLEXIBLE HOSE

ContiTech Schlauch GmbH, ...

1. A multilayer flexible hose comprising at least the following layer structure:a single-ply or multi-ply outer layer based on at least one elastomer;
at least one single-ply or multi-ply textile strength member layer;
at least one single-ply or multi-ply textile adhesive layer, wherein the adhesive layer contains as an adhesive at least member of the group consisting of zinc(II) salt of acrylic acid, zinc(II) salt of methacrylic acid, zinc(II) salt of monomethacrylic acid, and any combination thereof; and,
a single-ply or multi-ply inner layer based on at least one elastomer;wherein the adhesive is zinc diacrylate incorporated in the adhesive layer in an amount equal to or greater than 10 phr; and,wherein tear propagation resistance between the strength member layer and the adhesive layer is at least 113 N/mm according to ASTM D2229 T test.
US Pat. No. 10,966,990

MIDAZOLAM IN FLEXIBLE BAGS

InfoRLife SA, Campascio ...

1. A ready-to-use terminally sterilized, preservative-free aqueous midazolam solution in an intravenous laminated flexible plastic bag, comprising 0.25 to 1.5 mg/ml of midazolam, sufficient tonicity adjusting agent to provide an osmolality of from 260 and 320 mosm/kg and sufficient acid and optionally a base to provide a pH of from about 2.5 to 3.5 with the remainder water for injection;wherein:
the tonicity adjusting agent comprises at least one selected from the group consisting of sodium chloride, potassium chloride and calcium chloride;
the acid comprises hydrochloric acid;
the base, if present, comprises sodium hydroxide; and
the midazolam content after accelerated storage at 40° C. for six months is greater than 97%
the intravenous laminated flexible plastic bag comprises from 3 to 7 layers and has an innermost layer comprises an ethylene-vinyl acetate coplymer.
US Pat. No. 10,968,272

METHODS OF TREATING A CRYSTAL INDUCED ARTHROPATHY USING IL-1BETA ANTIBODIES

Novartis AG, Basel (CH)

1. A method of treating a crystal induced arthropathy in a patient in need thereof, comprising administering to the patient an effective amount of a human IL-1beta binding antibody comprising an antigen binding site comprising:a) at least one immunoglobulin heavy chain variable domain (VH) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, the CDR1 comprising the amino acid sequence set forth as SEQ ID NO: 3, the CDR2 comprising the amino acid sequence set forth as SEQ ID NO: 4, and the CDR3 comprising the amino acid sequence set forth as SEQ ID NO: 5; and
b) at least one immunoglobulin heavy chain variable domain (VL) which comprises in sequence hypervariable regions CDR1?, CDR2? and CDR3?, the CDR1? comprising the amino acid sequence set forth as SEQ ID NO: 6, the CDR2? comprising the amino acid sequence set forth as SEQ ID NO: 7, the CDR3? comprising the amino acid sequence set forth as SEQ ID NO: 8,
wherein the antibody is parenterally administered at a dose between 0.1-50 mg of the antibody per kg body weight of the patient.
US Pat. No. 10,966,991

PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC

CHIESI FARMACEUTICI S.P.A...

1. A process for preparing a powder formulation for inhalation for use in a dry powder inhaler, said powder comprising:(A) a carrier, comprising:
(a) 80 to 95 percent by weight, based on the total weight of said carrier, of coarse particles of a physiologically acceptable excipient having a mean particle size of at least 175 ?m; and
(b) 19.6 to 4.9 percent by weight, based on the total weight of said carrier, of micronized particles of a physiologically acceptable excipient, and 0.1 to 0.4 percent by weight, based on the total weight of said carrier, of a salt of a fatty acid; and
(B) micronized particles of an anti-muscarinic drug, a long-acting ?2-agonist, and optionally, an inhaled corticosteroid, as active ingredients, wherein said anti-muscarinic drug comprises glycopyrronium bromide, and said long-acting ?2-agonist comprises formoterol fumarate dihydrate,
said process comprising:
(i) mixing all of said coarse particles of a physiologically acceptable excipient; all of said salt of a fatty acid; a first portion of said micronized particles of a physiologically acceptable excipient; and all of said micronized particles of said long-acting ?2-agonist, said anti-muscarinic drug, and, optionally, said inhaled corticosteroid in a vessel of a shaker mixer at a speed of rotation not lower than 16 rpm for a time of not less than 60 minutes, to obtain a first mixture; and
(ii) adding the remaining part of said micronized particles of a physiologically acceptable excipient to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not lower than 16 rpm for a time of at least 120 minutes, to obtain said formulation,
wherein the extrafine particle fraction of each active ingredient is from 20 to 35%.
US Pat. No. 10,968,273

ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION

FUNDACIO PRIVADA INSTTTUC...

1. A method for the treatment of a cancer comprising increased expression of Leukemia inhibitor factor (LIF) as compared to a control sample; comprising administering a monoclonal antibody or antigen binding fragment thereof to a subject afflicted with cancer, wherein the monoclonal antibody or antigen binding fragment thereof is produced by the hybridoma deposited on Apr. 1, 2010 by Vall d'Hebron Institute of Oncology at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSM ACC3054).
US Pat. No. 10,966,992

VITAMIN D COMPOSITION

1. A vitamin D composition comprising vitamin D in contact with tomato seed oil, wherein said contact increases the bioavailability and stability of said vitamin D compared to control vitamin D that has not been contacted with said tomato seed oil.
US Pat. No. 10,968,274

ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF

Elixiron Immunotherapeuti...

1. An isolated antibody comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein said VH CDR1, VH CDR2, and VH CDR3 are SEQ ID NO: 120, SEQ ID NO: 121, and SEQ ID NO: 122, respectively; wherein said VL CDR1, VL CDR2, and VL CDR3 are SEQ ID NO: 132, SEQ ID NO: 133, and SEQ ID NO: 134, respectively.
US Pat. No. 10,966,993

PHARMACEUTICAL COMPOSITION COMPRISING A SULFONYLUREA DRUG AND PREPARATION METHOD THEREOF

JIANGSU AOSAIKANG PHARMAC...

1. A pharmaceutical composition for injection administration, comprising a sulfonylurea drug, a cyclodextrin and an additive;wherein said cyclodextrin is 2-hydroxypropyl-?-cyclodextrin and said additive is selected from sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, and meglumine.
US Pat. No. 10,968,275

ANTI-ROR1 ANTIBODIES AND USES THEREOF

FRED HUTCHINSON CANCER RE...

1. A binding protein comprising an antibody or an antigen-binding fragment thereof that specifically binds to a ROR1 protein, comprising:a light chain variable domain (VL) comprising a CDR1 comprising the sequence set forth in SEQ ID NO:31, a CDR2 comprising the sequence set forth in SEQ ID NO:33, and a CDR3 comprising the sequence set forth in SEQ ID NO:35; and a heavy chain variable domain (VH) comprising a CDR1 comprising the sequence set forth in SEQ ID NO: 23, a CDR2 comprising the sequence set forth in SEQ ID NO: 27, and a CDR3 comprising the sequence set forth in SEQ ID NO:29.
US Pat. No. 10,968,276

OPTIMIZED ANTI-CD3 VARIABLE REGIONS

Xencor, Inc., Monrovia, ...

1. A composition comprising an anti-CD3 binding domain, said anti-CD3 binding domain comprising:a) a variable heavy chain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:411; a vhCDR2 having the amino acid sequence of SEQ ID NO: 413; and a vhCDR3 having the amino acid sequence of SEQ ID NO: 417; and
b) a variable light chain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO: 420; a vlCDR2 having the amino acid sequence of SEQ ID NO: 425; and avlCDR3 having the amino acid sequence of SEQ ID NO: 433.
US Pat. No. 10,966,995

USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGS) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

THE TRUSTEES OF THE UNIVE...

1. A method for treating asthma in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of secoisolaricirecinol diglucoside (SDG).
US Pat. No. 10,968,277

GENE SIGNATURES FOR DETERMINING ICOS EXPRESSION

Jounce Therapeutics, Inc....

1. An isolated antibody comprising:a. (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 194; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 195; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 196; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 197; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 198; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 199; or
b. (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 202; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 203; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 204; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 205; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 206; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 207; or
c. (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 210; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 211; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 212; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 213; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 214; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 215.
US Pat. No. 10,968,278

COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME

SANOFI BIOTECHNOLOGY, Pa...

1. A method for treating macular edema in a subject in need thereof comprising administering an effective amount of an antibody that specifically binds human IL-6 receptor, wherein the antibody that specifically binds to the IL-6 receptor comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 2 and a light chain variable region comprising the sequence of SEQ ID NO: 3, wherein the antibody is administered every two weeks at a dose of about 150 or about 200 mg and wherein the subject has been treated for at least three months with a corticosteroid.
US Pat. No. 10,966,997

METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOWER BACK PAIN

ECM DIAGNOSTICS, INC., A...

1. A method for treating degenerative disc disease or chronic lower back pain, comprising:administering to a patient having degenerative disc disease or chronic lower back pain, and suspected of having a low-virulence infection, an antibiotic and an IL-1? inhibitor; wherein the IL-1? inhibitor is selected from the group consisting of anakinra, canakinumab, gevokizumab, and IL-1trap.
US Pat. No. 10,966,998

CANCER THERAPY VIA A COMBINATION OF EPIGENETIC MODULATION AND IMMUNE MODULATION

The Johns Hopkins Univers...

1. A method of treating a neoplastic condition in a human subject in need thereof consisting of:administering to the human subject (i) a first agent that is a DNA methyl transferase (DNMT) inhibitor and (ii) a second agent that is human or humanized anti-PD-1 antibody, thereby treating the neoplastic condition in the human subject,
wherein the neoplastic condition is lung cancer, colon cancer or ovarian cancer,
wherein the first agent is administered before the second agent, and
wherein the first agent increases PD-L1 protein level expression in the lung cancer, colon cancer or ovarian cancer.
US Pat. No. 10,968,280

BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF

BioNTech SE, Mainz (DE)

1. A multispecific antibody comprising a first antigen-binding region capable of binding to human CD137 and a second antigen-binding region capable of binding to human PD-L1, wherein the second antigen-binding region inhibits the binding of human PD-L1 to human PD-L1, wherein(i) the first antigen-binding region comprises
a first heavy chain variable region (VH) and a first light chain variable region (VL), wherein the first VH comprises the amino acid sequence as set forth in SEQ ID NO: 15, and
wherein the first VH comprises a first HCDR1 sequence, a first HCDR2 sequence, and a first HCDR3 sequence, wherein the first HCDR1 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 9, wherein the first HCDR2 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 10, and wherein the first HCDR3 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 11, and wherein the first VL comprises a first LCDR1 sequence, a first LCDR2 sequence, and a first LCDR3 sequence, wherein the first LCDR1 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 13, wherein the first LCDR2 sequence comprises the amino acid sequence GAS, and wherein the first LCDR3 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 14; and
(ii) the second antigen-binding region comprises a second heavy chain variable region (VH) and a second light chain variable region (VL), wherein the second VH comprises the amino acid sequence as set forth in SEQ ID NO: 17, and
wherein the second VH comprises a second HCDR1 sequence, a second HCDR2 sequence, and a second HCDR3 sequence, wherein the second HCDR1 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 18, wherein the second HCDR2 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 19, and wherein the second HCDR3 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 20, and wherein the second VL comprises a second LCDR1 sequence, a second LCDR2 sequence, and a second LCDR3 sequence, wherein the second LCDR1 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 22, wherein the second LCDR2 sequence comprises the amino acid sequence DDN, and wherein the second LCDR3 sequence comprises an amino acid sequence as set forth in SEQ ID NO: 23.
US Pat. No. 10,968,536

METHODS AND COMPOSITIONS FOR SEQUENCING

JUMPCODE GENOMICS, INC., ...

1. A method of generating a plurality of multi-insert nucleic acids, the method comprising: combininga) an insertional nucleic acid comprising an adapter sequence and an RNA promoter sequence that is flanked by nucleic acid integrase recognition sequences;
b) a plurality of target nucleic acids; and
c) a nucleic acid integrase,
wherein the nucleic acid integrase
i) cleaves one or more of the plurality of target nucleic acids to produce one or more recombination sites,
ii) recognizes the nucleic acid integrase recognition sequences;
iii) inserts the insertional nucleic acid into the one or more recombination sites to generate the plurality of multi-insert nucleic acids
d) providing a nucleic acid polymerase that binds to the RNA promoter sequence; and
e) amplifying the plurality of multi-insert nucleic acids or portions thereof, thereby producing a plurality of amplified nucleic acids,
wherein both strands of the plurality of multi-insert nucleic acids are amplified, and
wherein the plurality of target nucleic acids is obtained from a genomic sample from a single cell.
US Pat. No. 10,968,281

ANTI-LSP1 ANTIBODY

INSTITUT CURIE, Paris (F...

1. An anti-LSP1 (Leukocyte specific protein 1) single domain antibody comprising a variable domain that comprises three CDRs (complementarity determining regions), the first CDR (CDR1) consisting of SEQ ID NO: 1, the second CDR (CDR2) consisting of SEQ ID NO: 2 and the third CDR (CDR3) consisting of SEQ ID NO: 3.
US Pat. No. 10,967,000

CELL-PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME AND COMPOSITION COMPRISING SAME

1. A conjugate of a carrier peptide and an active ingredient,wherein the carrier peptide is an isolated peptide 16 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 1;
wherein the carrier peptide and the active ingredient are connected via a covalent bond, or via a linker;
and the active ingredient is not telomerase or a fragment thereof.
US Pat. No. 10,968,282

METHODS FOR SCREENING COMPOUNDS FOR INCREASING THERMOGENIC ADIPOCYTES

ACCELERON PHARMA INC., C...

1. A method of screening for a compound that is capable of increasing thermogenic adipocytes in a mouse, comprising:a) administering a compound to the mouse; and
b) determining the mRNA levels of uncoupling protein-1 (UCP1) in the mouse;
wherein if the compound increases UCP1 mRNA levels in the mouse, then the compound is capable of increasing thermogenic adipocytes.
US Pat. No. 10,967,001

METHOD OF TREATING INFLAMMATION

CYTOSORBENTS CORPORATION,...

1. A method of treating systemic, regional, or local inflammation in a patient, said method comprising administration of a therapeutically effective dose of a sorbent for an inflammatory mediator in said patient; wherein the sorbent is a biocompatible polymer;the biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof,
the biocompatible polymer having a pore structure such that the total pore volume of pore size in the range of 50 ? to 3000 ? is greater than 0.5 cc/g to 3.0 cc/g dry polymer; wherein the ratio of pore volume between 50 ? to 3,000 ? (pore diameter) to the pore volume between 500 ? to 3,000 ? (pore diameter) of the polymer is smaller than 200:1; or the ratio of pore volume between 50 ? to 3,000 ? in diameter to the pore volume between 1,000 ? to 3,000 ? in diameter of the polymer is greater than 20:1,
said sorbent being administered orally, via a feeding tube, peritoneally, or rectally;
wherein said inflammatory mediator is a cytokine produced in response to an infection in said patient chosen from endotoxemia, Bacillus anthracis (anthrax), influenza virus, smallpox virus, Yersinia pestis (plague), Ebola virus, Marburg virus, Francisella tularensis (tularemia), hantavirus, cholera toxin, botulinum toxin, ricin toxin, Salmonella, Escherichia coli, Shigella, or Listeria.
US Pat. No. 10,968,283

METHOD FOR PRODUCING FUNCTIONALIZED NANOCRYSTALLINE CELLULOSE AND FUNCTIONALIZED NANOCRYSTALLINE CELLULOSE THEREBY PRODUCED

Anomera Inc., Montreal (...

1. A method for producing functionalized nanocrystalline cellulose in the form of nanocrystals in one step, wherein the nanocrystals are between about 2 nm to about 20 nm in width and between about 80 nm and about 250 nm in length,the method comprising the steps of:
(a) providing cellulose,
(b) mixing said cellulose with a peroxide, thereby producing a reaction mixture, and
(c) heating and/or (c?) exposing to UV radiation the reaction mixture containing the cellulose and the peroxide until hydrolysis and oxidation by the peroxide of the cellulose into carboxylated nanocrystalline cellulose,
steps (c) and/or (c?) thereby producing carboxylated nanocrystalline cellulose that is free of surface sulfate groups as said functionalized nanocrystalline cellulose;
wherein the carboxylated nanocrystalline cellulose is produced at steps (c) and/or (c?) in the absence of mineral acids or inorganic persulfates; and
wherein the method does not comprise TEMPO oxidation.
US Pat. No. 10,967,002

ANIMAL FEED SUPPLEMENT AND METHOD

CAN TECHNOLOGIES, INC., ...

1. A method of feeding an animal, comprising:feeding a complete animal feed to the animal during at least one of the gestation and lactation phases, the complete animal feed comprising at least one of a gestation feed and a lactation feed, the complete animal feed comprising one or more nitrate compounds in an amount of less than 10 kg/metric ton of the total weight of the feed wherein the complete animal feed comprises a premix comprising
the one or more nitrate compounds, the one or more nitrate compounds being greater than about 50% by weight of the premix; and
vitamins and trace minerals;
wherein the premix is less than about five percent by weight (5.0 wt %) of the complete feed; and
feeding the feed to an animal on or after 110 days after gestation of the animal;
whereby the one or more nitrate compounds increase systemic vasodilation to reduce animal fatigue and reduce farrowing time, and increase vasodilation of at least one of the placenta and the mammary glands of the animal.
US Pat. No. 10,968,284

METAL OXIDE PARTICLES WITH UNIFORM MULTI-LAYER POLYMER COATINGS

The Regents of the Univer...

1. A process for preparing a multilayer composite comprising the steps of:a) contacting OH-functionalized porous inorganic-oxide particles with an excess of OH-reactive crosslinking agent to form metal oxide particles imbibed with the crosslinking agent; and
b) contacting the inorganic-oxide particles containing imbibed crosslinking agent with a solution of a polyhydroxyl-functionalized polymer under reactive coupling conditions;
wherein between steps a) and b), crosslinking agent neither bonded to nor imbibed with the inorganic-oxide particles is substantially, but not completely removed; and
where the inorganic oxides are oxides of Ti, Al, Si, Zn, Fe, Zr, Mn, Mg, Cr, Ce, Nb, W, B, or a combination thereof.
US Pat. No. 10,968,540

PROCESS FOR THE MANUFACTURE OF A SHAPED BODY

Stora Enso OYJ, Helsinki...

1. A method for manufacturing a shaped body comprising lignin, comprising the following steps:a) providing cellulose and/or a cellulose derivative,
b) providing lignin and/or a lignin derivative,
c) dissolution of said cellulose and/or a cellulose derivative, and lignin and/or a lignin derivative, followed by subsequent mixing thus providing a dope,
d) performing a shaping of the dope to a precursor material,
e) performing a coagulation of said precursor material in a bath containing a coagulation liquid, wherein the coagulation liquid comprises one or more salts, wherein said one or more salts have cations selected from the 1st, 2nd, or 3rd main groups of the periodic table and
f) drying of said precursor material, thus providing a shaped body comprising lignin.
US Pat. No. 10,968,285

MATRICES COMPRISING A MODIFIED POLYSACCHARIDE

1. A plastic surgery implant consisting essentially of a matrix comprising:at least one modified polysaccharide consisting of repeating disaccharide units, wherein the primary alcohol group is oxidized to a carboxylic acid group in at least 11% of the disaccharide units,
wherein the matrix further comprises at least one unmodified polysaccharide,
wherein the weight ratio of the modified polysaccharide to unmodified polysaccharide in the matrix is greater than 10 wt % of a modified polysaccharide, and
wherein the shear modulus G? of the matrix is in the range of from 10 Pa to 107 Pa.
US Pat. No. 10,969,309

VIRUS CONCENTRATION METHOD

KTEN BIO INC., Kobe (JP)...

1. A virus concentration method comprising:(a) adding a concentration liquid containing polyethylene glycol, salt and glycogen, either individually or in a mixed state, to a liquid in which the virus is suspended,
(b) subsequently centrifuging to concentrate the virus, and
wherein the glycogen has a final concentration of glycogen of 0.02-0.08% in the concentration liquid.
US Pat. No. 10,967,004

MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING THE PRODUCTS

1. A mineral pitch resin product in the form of a semisolid, solid, liquid or powder consisting of a pure form of at least one of gold, platinum and silver present in an amount above 1 ppm and below 100 ppm, and wherein the mineral pitch resin product has a mercury concentration that does not exceed 1 mg/kg, an arsenic concentration that does not exceed 6 mg/kg, and a glycine concentration of no less than 1%.
US Pat. No. 10,968,286

SITE-SELECTIVE MODIFICATION OF POLYSACCHARIDES AND APPLICATIONS THEREOF

B. G. Negev Technologies ...

1. A modified polysaccharide selectively modified at its reducing end by conjugation with a single aminoxy-Regioselective Addressable Functionalized Template (RAFT) peptide, wherein said RAFT peptide is a biologically active linear or cyclic RAFT peptide comprising an arginine-glycine-aspartate (RGD) sequence or an heparin binding peptide (HBP) sequence or a combination thereof, or a nuclear localizing sequence (NLS), said RAFT peptide selected from the sequence GGGGRGDYK(SEQ ID NO: 3), GGGGSPPRRARVTY (SEQ ID NO: 4), GGGGSPPLLALVTY (SEQ ID NO: 5), GGGGSPPRRARVTYK (SEQ ID NO: 6), YDGRGGG-(K—ONH2)-GGGGSPPRRARVTY-ONH2 (SEQ ID NO: 7), and GGGGPKKKRKVED (NLS; SEQ ID NO: 8).
US Pat. No. 10,967,005

MODIFIED T LYMPHOCYTES COMPRISING A BAFF ANTIBODY-INDUCIBLE CASPASE AND METHODS OF APOPTOSIS

CELGENE CORPORATION, Sum...

1. A T lymphocyte comprising an artificial cell death polypeptide, wherein said artificial cell death polypeptide is a transmembrane protein comprising an extracellular domain that comprises a B-cell activating factor (BAFF) epitope or mimotope, a transmembrane domain, and an intracellular domain comprising an apoptosis-inducing domain, wherein said apoptosis-inducing domain is caspase 3, caspase 8 or caspase 9, wherein said artificial cell death polypeptide is dimerizable using an anti-BAFF antibody that binds to said BAFF epitope or mimotope, and wherein when said antibody dimerizes said artificial cell death polypeptide, an apoptosis-inducing signal is generated in said T lymphocyte.
US Pat. No. 10,968,287

METHOD FOR PRODUCING HYDROGENATED CONJUGATED DIENE POLYMER LATEX

ZEON CORPORATION, Tokyo ...

1. A method for producing a hydrogenated conjugated diene polymer latex comprising:a hydrogenation step of dissolving or dispersing a hydrogenation catalyst containing a platinum group element in a latex of a conjugated diene polymer to hydrogenate a carbon-carbon unsaturated bond in the conjugated diene polymer;
an insoluble complex formation step of complexing the platinum group element with a complexing agent to form an insoluble complex; and
an insoluble complex removing step of continuously feeding the latex which has undergone the insoluble complex formation step to a centrifuge machine and continuously performing a centrifugation operation to continuously remove the insoluble complex from the latex and continuously discharge the insoluble complex out of the centrifuge machine;
wherein in the insoluble complex removal step the feed rate of the latex to the centrifuge machine is adjusted to 0.5 to 15 m3/hour, and the centrifugal force in the centrifugation operation is adjusted to 200 to 10,000 G.
US Pat. No. 10,967,006

STEM CELLS FOR WOUND HEALING

ABT Holding Company, Cle...

1. A method to promote wound healing of an ulcer in a subject by administering cells (I) in an effective amount and for a time sufficient to promote the wound healing in the ulcer, wherein the cells (I) are not delivered from a functionalized substrate, wherein the cells (I) are non-embryonic non-germ cells that express CD90 and oct4 or telomerase, are not transformed, are not tumorigenic, and have a normal karyotype.
US Pat. No. 10,968,288

STYRENE-FREE COATING COMPOSITIONS FOR PACKAGING ARTICLES SUCH AS FOOD AND BEVERAGE CONTAINERS

1. An inside spray coating composition comprising:an aqueous carrier; and
an emulsion-polymerized latex copolymer dispersed in the aqueous carrier, wherein the monomers used to produce the emulsion-polymerized latex copolymer are substantially free of BPA, PVC, halogenated monomers, and styrene; and
wherein the emulsion-polymerized latex copolymer is the reaction product of monomers emulsion polymerized in the presence of a polyolefin polymeric surfactant;
wherein the coating composition has an average viscosity ranging from about 5 seconds to about 40 seconds, pursuant to the Viscosity Test;
wherein the coating composition has a resin solids content ranging from about 10% by weight to about 30% by weight, based on a total weight of the coating composition; and
wherein the coating composition, when cured, has a glass transition temperature greater than 50° C.
US Pat. No. 10,967,007

CARDIAC STEM CELLS FOR CARDIAC REPAIR

University of Maryland, B...

1. A method of treating an individual for a cardiac medical condition, comprising the step of providing to the individual a therapeutically effective amount of a conditioned medium from neonatal cardiac stem cells that have the following characteristics: c-kit+, CD90+, CD44+, CD105+, CD31?, CD34?, CD45?, Nkx2.5+, tryptase negative, and SSEA4-.
US Pat. No. 10,967,008

PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF

Cell Ideas Pty Ltd, Gord...

1. A method of treating a non-inflammatory skin condition in a subject in need thereof, the method comprising topically administering to the subject a pharmaceutical composition comprising adipose tissue-derived secretions, in combination with a pharmaceutically acceptable carrier or diluent, wherein the skin condition is alleviated; wherein the skin condition is selected from the group consisting of: dry skin, wrinkling of the skin, thin skin, cracking of the skin, stretch marks, sun spots, age spots, liver spots, puffiness and/or dark circles around the eyes; andwherein the adipose tissue-derived secretions are prepared from an adipose suspension comprising adipose tissue-derived non-adipocyte cells by:
(i) exposing a sample of adipose tissue to a proteolytic enzyme solution to generate a cell suspension;
(ii) centrifuging the suspension of cells to form a cell pellet, a free lipid layer above a floating cell layer which comprises adipocytes and an intermediate layer between the cell pellet and the floating cell layer, said intermediate layer being depleted of cells relative to the cell pellet and the floating cell layer; and
(iii) removing the free lipid layer and the intermediate layer;
(iv) optionally removing adipocytes from the centrifuged material by removing part or all of the floating cell layer which comprises adipocytes;
(v) mixing the cell pellet and, if present, the floating cell layer comprising adipocytes, to form an adipose tissue derived cell suspension which may or may not include adipocytes;
(vi) culturing the cell suspension under appropriate conditions;
(vii) collecting a supernatant of the cell culture to obtain the adipose tissue-derived secretions.
US Pat. No. 10,968,802

METHOD FOR PREVENTING A SELECTIVE CATALYTIC REDUCTION (SCR) CATALYST FROM BEING CONTAMINATED WITH PLATINUM

1. A method for avoiding platinum group metal contamination of an SCR catalyst that is positioned for exhaust gas contact in an exhaust gas treatment system;comprising passing the exhaust gas into contact with a catalyst containing platinum group metal upstream of the SCR catalyst, the method further comprising passing the exhaust gas into contact with a material zone that contains a mixture of aluminum oxide and cerium oxide, which material zone is located upstream of the SCR catalyst receiving the exhaust gas.
US Pat. No. 10,967,009

AMNIOTIC MEMBRANE HYDROGEL AND METHODS OF MAKING

Wake Forest University He...

1. A method of inducing wound healing and tissue regeneration in a subject comprising contacting a wound at a treatment site on the subject with a composition comprising amniotic membrane and a scaffold comprising a hydrogel comprising a biopolymer and a synthetic polymer;wherein the biopolymer comprises at least one biopolymer selected from the group consisting of hyaluronan and gelatin;
wherein the synthetic polymer comprises at least one synthetic polymer selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PLA-PEO-PLA copolymers, PLA-PEO-PLGA copolymers, PLGA-PEO-PLA copolymers, PLGA-PEO-PLGA copolymers, poly(ethylene imine), and poly(ethylene glycol) diacrylate, wherein PLA is polylactic acid and PLGA is poly(lactide-co-glycolide); and
wherein the amniotic membrane is mixed within and dispersed in the scaffold.
US Pat. No. 10,967,010

COMPOSITIONS COMPRISING BACTERIAL STRAINS

4D Pharma PLC, Leeds (GB...

1. A method of treating a systemic condition in a subject characterized by elevated levels of Escherichia coli (E. coli) in a tissue or organ in need thereof, comprising administering to said subject a pharmaceutical composition that comprises at least 1×103 colony forming units (CFU) per gram of a bacteria strain of the genus Blautia with respect to a total weight of said pharmaceutical composition, wherein said bacteria strain comprises a 16S rRNA gene having at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein said administering is effective to treat said systemic condition in said subject.
US Pat. No. 10,967,011

COMPOSITIONS AND METHODS

Seres Therapeutics, Inc.,...

1. A therapeutic composition formulated for oral administration comprising a purified population of bacteria, an enteric coating, and a capsule, wherein the purified population of bacteria consist of spore-forming bacteria, and wherein at least one of the spore-forming bacteria are selected from the group consisting of Clostridium methylpentosum, Clostridium sp YIT 12069, Anaerofustis stercorihominis, Bacteroides galacturonicus, Bacteroides pectinophilus, Brachyspira pilosicoli, Clostridium beijerinckii, Clostridium carnis, Clostridium favososporum, Clostridium sp. L2-50, Clostridium sp. MT4 E, Clostridium sp. NML 04A032, Clostridium sp. SS211, Clostridium stercorarium, Clostridium xylanolyticum, Coprococcus sp. ART55/1, Deferribacteres sp. oral clone JV006, Desuljitobacterium frappieri, Exiguobacterium acetylicum, Lachnospira multipara, and Lachnospira pectinoschiza.
US Pat. No. 10,967,012

MICROBIOME-BASED INFORMED METHOD TO FORMULATE LIVE BIOTHERAPEUTICS

University of Maryland, B...

1. A method for treating bacterial vaginosis in a female human subject, comprising:administering a remedial live biotherapeutic formulation to the subject,
wherein the remedial live biotherapeutic formulation comprises bacteria adapted to remedy a deficiency or excess of at least one bacterial strain in the subject's vaginal microbial community, and
wherein the bacteria comprise a selected strain or consortium of strains comprising at least one of:
(i) Lactobacillus crispatus bacteria configured to express at least one of the asparagine synthase B (asnB) gene of SEQ ID NO: 2 and the asparagine synthase B (asnB) gene of SEQ ID NO: 3; and
(ii) Lactobacillus crispatus bacteria containing an asparagine synthase B (asnB) gene encoding at least one of a polypeptide of SEQ ID NO: 5 and a polypeptide of SEQ ID NO: 6.
US Pat. No. 10,968,294

PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS

BASF SE, Ludwigshafen (D...

1. A process for preparing high-reactivity isobutene homo- or copolymers with a content of terminal vinylidene double bonds per polyisobutene Chain end of at least 70 mol %, the process comprising:polymerizing isobutene or an isobutene-comprising monomer mixture in the presence of a complex, comprising a donor and an aluminum trihalide or an alkylaluminum halide,
wherein the donor comprises a mixture of at least two ethers selected from the group consisting of dimethyl ether, diethyl ether, di-n-propyl ether, diisopropyl ether, di-n-butyl ether, di-sec-butyl ether, diisobutyl ether, di-n-pentyl ether, di-n-hexyl ether, di-n-heptyl ether, di-n-octyl ether, di-(2-ethylhexyl) ether, methyl n-butyl ether, methyl sec-butyl ether, methyl isobutyl ether, methyl tert-butyl ether, ethyl n-butyl ether, ethyl sec-butyl ether, ethyl isobutyl ether, ethyl tert-butyl ether, n-propyl n-butyl ether, n-propyl sec-butyl ether, n-propyl isobutyl ether, n-propyl test-butyl ether, isopropyl n-butyl ether, isopropyl sec-butyl ether, isopropyl isobutyl ether, isopropyl tert-butyl ether, methyl n-hexyl ether, methyl n-octyl ether, methyl 2-ethylhexyl ether, ethyl n-hexyl ether, ethyl n-octyl ether, ethyl 2-ethylhexyl ether, n-butyl n-octyl ether, n-butyl 2-ethylhexyl ether, tetrahydrofuran, tetrahydropyran, 1,2-dioxane, 1,3-dioxane, 1,4-dioxane, dicyclohexyl ether, diphenyl ether, anisole, phenetole, ditolyl ether, dixylyl ether, and dibenzyl ether,
wherein acids employed in the process comprise only carboxylic acids, mineral acids, aluminum trihalides, alkylaluminum dihalides, and/or dialkyl aluminum halides.
US Pat. No. 10,968,295

ACRYLIC ACID POLYMERS NEUTRALIZED WITH SODIUM AND CALCIUM IONS AND HAVING A NARROW MOLECULAR WEIGHT DISTRIBUTION

BASF SE, Ludwigshafen (D...

1. A process for preparing aqueous solutions of acrylic acid polymers comprising polymerizing acrylic acid in feed mode with a free-radical initiator in the presence of a chain transfer agent in water as solvent, which process comprises(i) initially charging water and optionally acrylic acid in acidic, unneutralized form, optionally one or more ethylenically unsaturated comonomer, optionally the chain transfer agent, and optionally initiator,
(ii) adding acrylic acid, optionally one or more ethylenically unsaturated comonomers, aqueous free-radical initiator solution, and chain transfer agent,
(iii) adding a base to the aqueous solution after termination of the acrylic acid feed,
wherein, in step (iii), a base comprising sodium ions and a base comprising calcium ions are added in such amounts that 30% to 60% of the acid groups of the acrylic acid polymers are neutralized with calcium ions, 30% to 70% of the acrylic acid polymers are neutralized with sodium ions and 0% to 10% of the acid groups of the acrylic acid polymers are not neutralized, and
wherein the chain transfer agent is hypophosphite.
US Pat. No. 10,967,014

RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED IN TRANS

De Staat der Nederlanden,...

1. A method for producing a vaccine comprising Respiratory Syncytial Virus (RSV) virions comprising (i) a viral genome having a deletion or inactivation of only the gene coding for a G-attachment protein and (ii) a RSV G-attachment protein at its surface, the method comprising:(a) infecting a culture of a first host cell with a RSV comprising a viral genome having the deletion or inactivation, wherein the first host cell is a Vero cell that comprises an expression vector which directs expression of the RSV G-attachment protein in the first host cell;
(b) recovering the virions from the infected first host cell culture; and
(c) formulating the produced RSV virions with a pharmaceutically acceptable excipient into a vaccine.
US Pat. No. 10,968,296

AIR VOID CONTROL COMPOSITION FOR CARBONYL-CONTAINING MONOMER POLYMERIZATION

Arkema France, Colombes ...

1. A process for producing a low defect fiber-reinforced poly(meth)acrylate composite article comprising the step of adding to a reaction composition comprising a liquid (meth) acrylic syrup, from 200 to 5000 ppm of one or more primary or secondary aliphatic amines, wherein said low defect article contains less than 10 volume percent of air voids,wherein said (meth)acrylic syrup comprises methyl methacrylate monomer and from 1 to 80 weight percent of (meth)acrylic polymer dissolved in said (meth)acrylic monomer, based on the reaction composition, and; wherein the dynamic viscosity value of the liquid (meth)acrylic syrup is between 10 mPa·s and 10,000 mPa·s.
US Pat. No. 10,967,016

TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF

INFINITUS (CHINA) COMPANY...

1. A method of inhibiting the growth of tumor, increasing the percentage of CD4+ and CD8+ cells in lymphocytes of tumor stroma, decreasing VEGF and TGF-?1 positive cells in tumor tissue, enhancing immunity, preventing and/or assisting in treating tumor, and/or restoring normal immune function, comprising administrating an effective amount of a traditional Chinese medicine composition to a subject in need thereof;wherein the traditional Chinese medicine composition comprises GANODERMA polysaccharide, MORINDAE OFFICINALIS RADIX polysaccharide, POLYGONATI RHIZOMA polysaccharide, ANGELICAE SINENSIS RADIX oil and MYRISTICAE SEMEN oil,
wherein the weight ratio of GANODERMA polysaccharide, MORINDAE OFFICINALIS RADIX polysaccharide, POLYGONATI RHIZOMA polysaccharide, ANGELICAE SINENSIS RADIX oil and MYRISTICAE SEMEN oil is (1 to 5):(1 to 5):(1 to 5):(1 to 5):(1 to 5).
US Pat. No. 10,968,298

SYNTHESIS OF 2,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS

HONEYWELL INTERNATIONAL I...

1. A process of synthesizing a copolymer consisting essentially of a copolymer formed from 2,3,3,3-tetrafluoropropene and vinylidene fluoride monomers, the process comprising the step of conducting an aqueous emulsion copolymerization of said monomers in the presence of a water soluble radical initiator to form the 2,3,3,3-tetrafluoropropene/vinylidene fluoride copolymer having 2,3,3,3-tetrafluoropropene as the major monomer unit, wherein the copolymerization is carried out at a temperature from about 55° C. to about 70° C.
US Pat. No. 10,967,017

TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF

INFINITUS (CHINA) COMPANY...

1. A method of inhibiting the growth of tumor, increasing the percentage of CD4+ and CD8+ cells in lymphocytes of tumor stroma, decreasing VEGF and TGF-?1 positive cells in tumor tissue, enhancing immunity, preventing and/or assisting in treating tumor, and/or restoring normal immune function, comprising administrating an effective amount of a traditional Chinese medicine composition to a subject in need thereof, wherein the traditional Chinese medicine composition comprises GANODERMA polysaccharide, GRIFOLA FRONDOSA polysaccharide, ANGELICAE SINENSIS RADIX oil and CINNAMOMI CORTEX oil, wherein the weight ratio of GANODERMA polysaccharide, GRIFOLA FRONDOSA polysaccharide, ANGELICAE SINENSIS RADIX oil and CINNAMOMI CORTEX oil is (1 to 5): (1 to 5): (1 to 5): (1 to 5).
US Pat. No. 10,967,018

METHODS FOR EXTRACTION AND ISOLATION OF ISOPRENOID AND TERPENE COMPOUNDS FROM BIOLOGICAL EXTRACTS

Concentrated Consulting G...

1. A method of extracting terpene and isoprenoid compounds from plant material and for selectively enriching the concentration of isoprenoid compounds in a fraction of this extract comprising the steps of:a. placing plant material into an extraction chamber, wherein the plant material comprises female flowers of Cannabis;
b. degassing the extraction chamber;
c. introducing chilled solvent into the extraction chamber such that extract-containing solvent forms;
d. filtration of the extract-containing solvent;
e. removal of the extract-containing solvent from the extraction chamber;
f. placing extract-containing solvent on a surface prior to placing the extract-containing solvent into a centrifuge vessel, the surface being capable of being placed into a vacuum oven;
g. placing the extract-containing solvent into a centrifuge vessel;
h. centrifuging the centrifuge vessel to promote formation of crystals and to separate said crystals from supernatant solvent; and
i. collecting the crystals.
US Pat. No. 10,968,300

CONTROL OF POLYMER NETWORK STRUCTURES VIA NANOGELS

THE REGENTS OF THE UNIVER...

1. A method of increasing a polymerization reaction rate of a base monomer composition, the method comprising combining an effective amount of a nanogel with the base monomer composition to form a monomer-nanogel mixture;wherein the base monomer composition comprises a monomer selected from the group consisting of methyl methacrylate (MMA), n-butyl acrylate, isobornyl acrylate, and combinations thereof; and
wherein the nanogel is soluble in the base monomer composition and wherein the nanogel is derived from a nanogel-forming monomer mixture that comprises:
at least one monovinyl monomer;
at least one divinyl monomer;
a chain transfer agent; and
an initiator.
US Pat. No. 10,968,556

MITIGATION OF ODOR IN CLEANING MACHINES AND CLEANING PROCESSES

Novozymes Biologicals, In...

1. A method of inhibiting or reducing production of laundry malodor caused by at least one malodor causing bacteria comprising contacting a fabric or a laundry washing machine with a Bacillus strain having the deposit accession number NRRL B-50136, which inhibits or reduces production of malodor caused by the at least one malodor causing bacteria.
US Pat. No. 10,967,019

METHOD FOR PROTECTING MITOCHONDRIA IN RETINA CELL

TAIWAN MITOCHONDRION APPL...

1. A method for protecting mitochondria in retina cells under or exposed to ultraviolet light, comprising:administrating to said retina cells an effective amount of a composition containing an emblica extract, wherein said administrating results in improvement of the ability of the mitochondria in performing oxidative phosphorylation for the synthesis of the adenosine triphosphate (ATP) and improvement of coupling efficiency of the synthesis of the adenosine triphosphate by the mitochondria,
wherein the emblica extract comprises 35-55 wt % of a mixture of Emblicanin-A and Emblicanin-B, 4-15 wt % of Punigluconin, 10-20 wt % of Pedunculagin, 5-15 wt % of Rutin and 10-30 wt % of Gallo-ellagitannoids.
US Pat. No. 10,968,301

STRESS-RESPONSIVE COMPOSITIONS AND USES THEREOF

UNIVERSITY OF DELAWARE, ...

1. A stress-responsive composition comprising (1) at least one (co)polymer comprising at least one mechanophore and (2) at least one compound comprising at least one functional group capable of reacting with a free radical, wherein the at least one mechanophore comprises at least one functional group selected from the group consisting of thiocarbonylthio, trithiocarbonate, dithiocarbamate, xanthate, dithiobenzoate, and any combination thereof.
US Pat. No. 10,971,635

CONDUCTIVE POLYMER NANOWIRES—GRAPHENE HYBRIDS WITH IMPROVED OPTOELECTRONIC PROPERTIES

BROOKHAVEN SCIENCE ASSOCI...

6. A method of making a hybrid photodetector comprising (1) providing regioregular poly (3-hexylthiophene) (P3HT) and atomically thin graphene; (2) either using a Whiskers method or a mixed solvent method to make the regioregular P3HT self-assemble into P3HT nanowires; and (3) either dropping or spin-casting the P3HT nanowires onto the graphene to form a conductive nanowire mesh hybrid photodetector.
US Pat. No. 10,967,020

METHOD OF SYNTHESIZING CUSTARD APPLE PEEL NANOPARTICLES

King Saud University, Ri...

1. A method of synthesizing Annona reticulata custard apple peel nanoparticles, consisting of:(a) extracting Annona reticulata custard apple peels in a solvent to produce a Annona reticulata custard apple peel extract;
(b) spraying the custard apple peel extract into boiling water under ultrasonic conditions to form a mixture;
(c) sonicating the mixture to provide a sonicated mixture;
(d) stirring the sonicated mixture to provide a stirred mixture; and
(e) drying the stirred mixture to obtain Annona reticulata custard apple peel nanoparticles.
US Pat. No. 10,967,021

ORAL COMPOSITIONS AND ROUTE OF ADMINISTRATION FOR THE DELIVERY OF A THYLAKOID EXTRACT

1. A method for manufacture of an oral composition, the method comprising the steps of:mixing a purified active thylakoid extract with an orally-acceptable non-aqueous carrier, wherein the composition when ingested in a subject, has antioxidant and anti-inflammatory activity.
US Pat. No. 10,967,022

BOTANICAL EXTRACT FOR SKIN CARE

Innophos, Inc., Cranbury...

1. A composition comprising:a botanical extract of the testa of the seed of Anacardium occidentale L.,
wherein the botanical extract has been standardized to a catechin content of about 15.0 w/w % or greater, based on total weight of the extract, and
wherein the botanical extract is present in the composition in a therapeutically effective amount of from about 125.0 ?g/mL to about 1000.0 ?g/mL,
and a carrier,
wherein the composition is effective in inhibiting tyrosinase activity.
US Pat. No. 10,967,023

PREPARATION OF A CHINESE MEDICINAL COMPOSITION INCLUDING GINSENG, GINKGO LEAF AND STIGMA CROCI

Shineway Pharmaceutical G...

1. A method of preparing a Chinese medicinal composition consisting of ginseng extract, Ginkgo leaf extract, and stigma croci extract, the method comprising:adding ginseng, ginkgo leaf and stigma croci in weight proportions of 1:0.8-1.5:0.018-0.030,
preparing ginseng extract, preparing ginkgo leaf extract, preparing stigma croci extract, and
mixing the ginseng extract, the ginkgo leaf extract and the stigma croci extract to form a composition consisting of ginseng, ginkgo leaf and stigma croci.
US Pat. No. 10,968,305

RENEWABLE SOURCE-DERIVED POLYMER OIL MACROINITIATORS AND THERMOPLASTIC BLOCK COPOLYMERS DERIVED THEREFROM

ARCHER DANIELS MIDLAND CO...

1. A method of making a thermoplastic polymer block suitable for polymerization with one or more other, different polymer blocks or suitable for use as a thermoplastic elastomer without combination with one or more other, different monomers or polymer blocks, comprising:providing a polymerization macroinitiator in the form of at least one halogenated polymer oil selected from the group consisting of: a halogenated heat-bodied, renewable source-derived oil; a halogenated blown, renewable source-derived oil; a halogenated, renewable source-derived copolymer oil; a halogenated hydrogenated heat-bodied, renewable source-derived oil; a halogenated hydrogenated blown, renewable source-derived oil; a halogenated hydrogenated renewable source-derived copolymer oil; and combinations of any thereof;
combining the polymerization macroinitiator with a suitable atom transfer radical polymerization catalyst in the form of a transition metal halide and with a solvent for the polymerization macroinitiator, but in the absence of any atom transfer radical polymerization initiator other than a polymerization macroinitiator as described above; and
in solution, causing an atom transfer radical polymerization of the polymerization macroinitiator with itself via one or more sites wherein a fatty acid double bond of the oil has been halogenated, a free hydroxyl group of the oil has been halogenated or an alpha carbon of a fatty acid moiety of the oil has been halogenated and via residual unsaturation in the polymerization macroinitiator.
US Pat. No. 10,967,024

SYNERGISTIC HERBAL STIMULANT COMPOSITIONS

1. A synergistic herbal stimulant composition comprising an efficacious combination, in substantially equal proportions by weight, of herbal stimulant ingredients and one synergist herbal ingredient, wherein the herbal stimulant ingredients are Horny Goat Weed (Epimedium Sagittatum), Rhodiola Root (Rhodiola Rosea), Elueuthero Root (Eleutherococcus), Nettle Leaf (Urticaria Dioica), Ashwagandha Root (Withania Somnifera), Maca Root (Lepidium Meyenii) and Moringa Root (Moringa Oleifera), and wherein the synergist herbal ingredient is Moses-in-a-basket (Tradescantia Spathacea).
US Pat. No. 10,968,306

BOUND STOPPER AND PRODUCTION METHOD THEREFOR

BASF INOAC Polyurethanes ...

1. A bound stopper which is made of a polyurethane foam and is to be mounted on a piston rod of a shock absorber for a vehicle, the bound stopper comprising:a polyurethane foam obtained from a polyurethane foam composition containing an isocyanate component and a blowing agent,
wherein the isocyanate component contains a urethane prepolymer having an isocyanate group, the urethane prepolymer being obtained from a polyol component, a polyrotaxane containing a cyclic molecule having an active hydrogen group as a constituent, and an isocyanate, and
the urethane prepolymer having an isocyanate group has an NCO % of 2.5% to 7.5%.
US Pat. No. 10,967,025

HERBAL NUTRACEUTICAL FORMULATION TO REDUCE OXIDATIVE STRESS, VIRAL AND MICROBIAL INFECTIONS, AND INFLAMMATION

Moringo Organics Inc., B...

1. A method of reducing oxidative stress in a human subject comprising administering to said subject in need thereof a therapeutically effective amount a herbal nutraceutical formulation,wherein the herbal nutraceutical formulation comprises the ingredients:
(a) about 100-150 mg Moringa Oleifera Leaf Powder;
(b) about 30 mg to 80 mg of Oregano Vulgare Leaf Extract;
(c) about 30 mg to 40 mg of Rosemary Leaf Extract;
(d) about 40 mg of Shilajit extract;
(e) about 30 mg to 40 mg of Pomegranate Peel Extract;
(f) about 40 mg of Spirulina;
(g) about 40 mg to 50 mg of Amla fruit extract;
(h) about 60 mg of Fenugreek seed extract;
(i) about 10 g of Curcuma longa extract; and
(j) about 2 mg of Pipeline extract.
US Pat. No. 10,968,563

THERMAL INSULATION SHEET AND METHOD FOR PRODUCING THE SAME, AND ELECTRONIC DEVICE AND BATTERY UNIT

PANASONIC INTELLECTUAL PR...

1. A method for producing a thermal insulation sheet, comprising:composite-forming including impregnating a nonwoven fabric with a basic sol prepared by adding a carbonate ester to a water glass composition to form a hydrogel-nonwoven fabric composite;
surface-modifying including mixing the composite with a silylating agent for surface modification; and
drying including removing liquid contained in the composite through drying at a temperature lower than a critical temperature of the liquid under a pressure lower than a critical pressure of the liquid, wherein
the thermal insulation sheet exhibits a compressibility of 40% or lower at 0.30 to 5.0 MPa.
US Pat. No. 10,967,026

MACA COMPOSITIONS AND METHODS OF USE

JDS Therapeutics, LLC, P...

1. A method of decreasing cytokine activity in a subject in need thereof comprising:administering a nutritional supplement to a subject in need thereof wherein the nutritional supplement comprises:
an effective amount of a maca composition (Lepidium meyenii) to decrease cytokine activity in the subject, wherein the maca composition comprises a synergistic combination consisting of black maca and yellow maca in a ratio of about 1:1;
wherein the maca composition has between about 250 mg and about 450 mg of total polyphenols per 100 grams of the maca composition;
wherein the maca composition has between about 200 and about 700 mg of total glucosinolates per 100 grams of the maca composition; and
wherein the nutritional supplement is provided in a dosage form selected from the group consisting of a tablet, a dispersible powder or granule, emulsion, hard capsule, or soft capsule; and
decreasing the cytokine activity in the subject.
US Pat. No. 10,967,027

EXTRACTS OF CYCLANTHERA PEDATA AND FORMULATIONS AND USES THEREOF

PROCAPS S.A., Barranquil...

1. A pharmaceutical composition for lowering serum cholesterol comprising an effective amount of a solid-form Cyclanthera Pedata extract and a pharmaceutically acceptable carrier, wherein the extract is obtained by the steps of:(a) immersing fresh fruit from a Cyclanthera Pedata plant in an aqueous solution containing peracetic acid for a period of time of about 2 minutes to 10 minutes,
(b) cutting the fruit into strips and removing the seeds and mucilage from said strips,
(c) drying the seedless strips at a temperature between 10° C. and 80° C.,
(d) milling the dried strips to produce particles having a size of about 2-10 mm,
(e) extracting the milled particles by immersing them in ethanol and performing an extraction process selected from the group consisting of: maceration, ultrasound-assisted extraction, microwave-assisted extraction, percolation, Soxhlet extraction, pressurized solvent extraction, extraction under reflux, countercurrent extraction and steam distillation, for a period of time of about 30 minutes to about 15 days to obtain a liquid extract,
(f) concentrating the liquid extract from step (e) to between 20% to 80% solids, and
(g) absorbing the concentrated extract in a microcrystalline cellulose matrix to yield the Cyclanthera Pedata in solid form.
US Pat. No. 10,967,028

COMPOSITION FOR HAIR LOSS PREVENTION OR HAIR GROWTH STIMULATION COMPRISING ARTEMISIA UMBELLIFORMIS EXTRACT

AMOREPACIFIC CORPORATION,...

1. A method for promoting proliferation of hair follicle cells in a subject having hair loss, comprising topically administering to an area in need thereof an effective amount of a composition comprising a hydro-ethanolic extract of Alpine wormwood (Artemisia umbelliformis), wherein the composition comprises at least 0.2 wt % of the extract based on the total weight of the composition, and wherein the composition is a cosmetic composition or pharmaceutical composition.
US Pat. No. 10,967,029

METHOD OF USING CISTANCHE TUBULOSA EXTRACT TO PREVENT, SLOW DOWN, OR TREAT AN EYE DISEASE CAUSED BY OXIDATIVE STRESS

Sinphar Pharmaceutical Co...

1. A method of treating an eye disease caused by oxidative stress from blue light irradiation comprising: administrating to a subject in need thereof a therapeutically effective amount of an aqueous extract of Cistanche tubulosa, wherein the extract contains echinacocide, aceteoside, isoacteoside, and tubuloside A, and wherein the eye disease is macular degeneration and/or retinopathy.
US Pat. No. 10,968,311

WHOLLY AROMATIC LIQUID CRYSTALLINE POLYESTER RESIN, MOLDED ARTICLE, AND ELECTRIC AND ELECTRONIC COMPONENTS

1. A wholly aromatic liquid crystalline polyester resin comprising,a polymer prepared by polymerization of monomers giving the following structural units (I), (II), (III), and (IV):
structural unit (I) derived from p-hydroxybenzoic acid,
structural unit (II) derived from 6-hydroxy-2-naphthoic acid,
structural unit (III) derived from an aromatic diol compound,
structural unit (IV) derived from an aromatic dicarboxylic acid, wherein
the composition ratio (mol %) of said structural units (I) to (IV) satisfies the following conditions:
2 mol %?structural unit (I)?9 mol %
40 mol %?structural unit (II)?75 mol %
9 mol %?structural unit (III)?24 mol %
9 mol %?structural unit (IV)?24 mol %.
US Pat. No. 10,968,567

METHOD FOR PREPARING ?-CELLULOSE, SPINNING COMPOSITION, AND FIBER MATERIAL

INDUSTRIAL TECHNOLOGY RES...

1. A method for preparing ?-cellulose, comprising:providing a coffee residue;
subjecting the coffee residue to a decolorization treatment, obtaining a white powder;
reacting the white powder with an alkaline solution after the decolorization treatment, obtaining a mixture, wherein the alkaline solution comprises sodium hydroxide and water, wherein the weight ratio of sodium hydroxide to water is from 18:100 to 25:100, and wherein the weight ratio of the white powder to sodium hydroxide is from 1:1 to 1:2; and
filtering the mixture to produce a filter cake and then baking the filter cake to obtain ?-cellulose.
US Pat. No. 10,967,030

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING PSORIASIS AND METHOD FOR PREPARING THE SAME

Beijing Zhendong Guangmin...

1. A traditional Chinese medicine composition effective for treating psoriasis, consisting of:20-80 parts (w/w) extract of dry roots of a plant of genus Rumex, wherein the plant is selected from the group consisting of R. patientia, R. crispus, R. nepalensis, R. dentatus, R. obtosifolius, R. japonicus, R. acetosa, R. trisetifer, R. chalepensis, R. gmehnii, and R. hastatus; and
20-80 parts (w/w) of dry roots of Sophora flavescens Ait,
prepared by a method comprising:
preparing the extracts wherein individual components having corresponding weight parts in the composition are obtained respectively, and broken into coarse grains, mixed uniformly, the resulting mixture is immersed in a solvent of water or 50-100% pharmaceutical ethanol at about 40 degrees for about 0.5 to 1 hour, then is extracted for three times by heating refluxing, each extraction time is 1-2 hours and the total amount of solvents is 15-20 (L/kg); the reflux solution is subjected to sedimentation separation under atmospheric pressure, treated by one or two of suction filtration or centrifugation (4000 rpm, 30 min) to obtain the extract solution; solvents the in extract solution are recovered by treatment of one or two selected from evaporation concentration under reduced pressure or film concentration at 60° C. or below to provide a concentrate; and the concentrate is dried under vacuum at 60° C. or below to provide the extracts; the extract is pulverized into fine powder, which is prepared into suitable formulations;
preparing refined products, including:
refining the extracts obtained by using ethanol, wherein firstly includes being treated by water sedimentation, the water-insoluble precipitated after treating is dried under vacuum and stored, the remaining aqueous solution is separated by any one of macroporous adsorption resin columns selected from AB-8, SP-825, or X-5, in which the diameter-length ratio of the resin column is 1:6-1:10, the column is eluted with water at a flow rate of 2-9 BV/h to remove impurities such as saccharides and inorganic salts, and then is gradiently eluted with 5%-100% ethanol at a flow rate of 3-10 BV/h, the eluate is collected, concentrated under reduced pressure, vacuum dried and combined with the water insoluble precipitates to provide the refined products; or
refining method of water extracts extracted by water, wherein the water extracts are precipitated with several times of ethanol to provide ethanol precipitate and ethanol soluble substance, the macromolecular impurities in the ethanol precipitate are discarded; the water-insoluble substance in the ethanol-soluble portion is dried and stored; the water-insoluble substance is subjected to macroporous resin adsorption or polyamide chromatography to remove small molecular sugars and inorganic salts, or is treated by membrane separation technology to remove impurities; when the impurities are removed by macroporous adsorption resin in which a column having a diameter-length ratio of 1:6 to 1:10 is used, the column is eluted with water at a flow rate of 5-2 BV/h to remove small molecular saccharides and inorganic salts, and then eluted gradiently with 5%-100% ethanol at the flow rate of 3-10 BV/h; the eluate is collected, concentrated under reduced pressure, dried under vacuum, and combined with the dry substance of the water insoluble substance to provide the refined products.
US Pat. No. 10,968,312

METHOD FOR MANUFACTURING POLYALKOXYLATED POLYMERS

SOLVAY SPECIALTY POLYMERS...

1. A process for the manufacture of an alkoxylated derivative of a hydrogenated or (per)halogenated polymer comprising at least one —OH group [polymer (PALK-OH)], said process comprising the steps of:(a) contacting at least one pre-catalyst C complying with formula (1)
E(Q)t  (1)
wherein
E is an element selected from IV-group metals, post-transition metals and silicon,
Q is chlorine, bromine, iodine or an optionally fluorinated alkoxy or aryloxy group, and
t is an integer corresponding to the valence of E;
with
(a-i) at least one polymer (POH), wherein polymer (POH) is a hydrogenated or (per)halogenated polymer comprising at least one —OH group,
thus providing a mixture (Ma-1) comprising said polymer POH and a product (C-POH) obtained by the reaction between said pre-catalyst C and said polymer (POH), or
(a-ii) at least one compound (I), wherein compound (I) is a source of iodine, thus providing a mixture (Ma-2) comprising said pre-catalyst C and said compound (I);
(b) contacting said mixture (Ma-1) with at least one compound (I), wherein compound (I) is a source of iodine or
contacting said mixture (Ma-2) with at least one polymer (POH),
thus obtaining mixture (Mb) comprising said polymer (POH), said product (C-POH) and said compound (I);
(c) contacting said mixture (Mb) with at least one alkylene oxide,
thus obtaining polymer (PALK-OH), optionally in admixture [mixture (Mc)] with said polymer (POH), said product (C-POH) and/or said compound (I).
US Pat. No. 10,968,568

METHOD FOR THE PRODUCTION OF PAPER, CARTON, OR CARDBOARD USING BAOBAB TREE BARK BAST FIBERS, BAOBAB FRUIT FIBERS, AND/OR NATAL FIG BAST FIBERS AS PAPER RAW MATERIAL

HOPE TREE INTERNATIONAL G...

1. A method for the production of paper, cardboard, or carton comprising the following steps:a) obtaining baobab fruit fiber and, optionally, baobab bark bast fiber and/or Natal fig bast fiber as a tree raw material, wherein the tree raw material comprises at least 5% baobab fruit fiber,
b) defibering the tree raw material of step a) while adding water in a defibering apparatus,
c) heating the fiber pulp obtained in step b),
d) applying the fiber pulp on a sieving means for removing a fraction of the added water to create a non-woven fabric of paper fiber,
e) pressing the non-woven fabric of paper fiber obtained in step d), and
f) drying the non-woven fabric of paper fiber obtained in step e).
US Pat. No. 10,967,031

SYNERGISTIC HERBAL COMPOSITIONS WITH PREBIOTIC PROPERTIES FOR TREATMENT OF SKIN INFECTIONS, ALLERGIES AND INFLAMMATION

KAMEDIS LTD., Tel Aviv (...

1. A method of treating atopic dermatitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising 0.02-5.0 (v/v) water extracts of each of Sanguisorbae officinalis, and Ailanthus altissima, wherein the extracts are produced by water extraction and further purified using a resin chromatography comprising macroporous resin.
US Pat. No. 10,968,569

POLYVINYL ALCOHOL STABILIZED ACETATE ETHYLENE COPOLYMER DISPERSIONS AS ADHESIVES FOR CREPED WEBS

WACKER CHEMIE AG, Munich...

1. In a crepe process comprising applying an adhesive composition to a nonwoven web, drying, and creping the nonwoven web on a creping drum, the improvement comprising applying an adhesive composition comprising an aqueous copolymer dispersion obtained by emulsion polymerization of a monomer mixture comprising 65 to 94.5% by weight of vinyl acetate, 5 to 30% by weight of ethylene, (meth)acrylamide, and 0.1 to 4% by weight of an N-methylol functional monomer, wherein the N-methylol functional monomer constitutes from 25 to 85% by weight of the combined amounts of (meth)acrylamide and N-methylol functional monomer, said combined amounts constituting from 0.5 to 4% by weight of the monomer mixture;wherein the emulsion polymerization is performed in the presence of 1 to 10% by weight of polyvinyl alcohol, based in each case on the total weight of all monomers used for the polymerization;
wherein the adhesive composition does not comprise any of the following types of surfactant:
alkylphenol ethoxylate, phosphate ester, or sodium laureth sulfate, and wherein the polyvinyl alcohol has a degree of hydrolysis in a range from 86% to 89 mol %, wherein the polyvinyl alcohol is present in an amount of from 2.5 to 10% by weight.
US Pat. No. 10,967,032

OPTIMUM RATIO FOR HERBS COMBINATION OBTAINED BY USING SCIENTIFIC-BASED FORMULA FOR HYPERTENSION TREATMENT AND A COMPOSITION THEREOF

Mun Fei Yam, Pulau Pinan...

1. A method for obtaining a composition for treating hypertension and hypertension-related complications, the method comprising:i. drying Uncaria rhynchophylla, Pueraria thomsonii, Panax notoginseng, and Alisma orientale;
ii. grinding the dried Uncaria rhynchophylla, Pueraria thomsonii, Panax notoginseng, and Alisma orientale into powder;
iii. mixing the ground dried Uncaria rhynchophylla, Pueraria thomsonii, Panax notoginseng, and Alisma orientale in a weight ratio ranging from 2.32-7.35:0.44-4.44:7.24-11.24:1-3, respectively, to form a mixture;
iv. subjecting the mixture to an extraction method selected from the group consisting of maceration, liquid-liquid extraction, decoction, solid-phase extraction, solid-phase microextraction, Soxhlet extraction, and fizzy extraction; and
v. separating an extract containing the composition from the mixture, wherein the extraction method is carried out at 50° C. and a solvent for the extraction method is ethanol.
US Pat. No. 10,968,314

POLYMER POWDER FOR POWDER BED FUSION METHODS

Evonik Operations GmbH, ...

1. A polymer powder, comprising:at least one polymer selected from the group consisting of polyamide and copolyamide in powder form coated with a hydrophobic substance having a melting point of below 90° C., wherein the hydrophobic substance is dissolved and applied at a temperature not more than 80° C. and then dried, the hydrophobic substance being at least one selected from the group consisting of a saturated fatty alcohol, an unsaturated fatty alcohol, a saturated fat, an unsaturated fat, a wax, a lactam, an alkene, and an alkane, wherein the coating is not a mixture of the hydrophobic substance and the at least one polymer, and wherein the polymer powder comprises 0.15% to 20% by weight of the hydrophobic substance, based on the total weight of the polymer powder.
US Pat. No. 10,967,033

FORMULATIONS FOR THE TREATMENT AND PREVENTION OF OBESITY

Indena S.P.A., Milan (IT...

1. A composition for treating obesity comprising:a) 100 mg extract of Phaseolus vulgaris having an ?-amylase inhibitor content of 300 g/mg and a lectin value of 10000 U/mg;
b) 50 to 200 mg extract of Cynara scolymus having a caffeoylquinic acid content ranging between 20 and 70%;
c) 25 mg extract of Echinacea angustifolia;
d) 200 mg extract of Vitis vinifera;
mixed with suitable excipients,
wherein the composition is in the form of tablets, dragees, soft or hard gelatin capsules or cellulose capsules.
US Pat. No. 10,967,034

MUSCADINE TOPICAL COMPOSITION WITH LOW CONTENT OF CONDENSED TANNIN

Shaklee Corporation, Ple...

1. A method of producing a decolorized muscadine grape pomace extract with lowered condensed tannin content, the method comprising:(a) preparing a precursor muscadine grape pomace extract from muscadine grapes,
(b) clarifying the precursor muscadine grape pomace extract by microfiltration to remove solids, thereby producing a clarified extract,
(c) processing the clarified extract by ultrafiltration through an about 500 to about 5000 kDa microfiltration membrane to obtain a first permeate and a first retentate, wherein flavor components are removed in the first permeate, and
(d) processing the first retentate by ultrafiltration through an about 25 to an about 100 kDa ultrafiltration membrane to obtain a second permeate and a second retentate,
wherein polymeric condensed tannins are retained in the second retentate and the second permeate has increased levels of polyphenols and lowered levels of sugars and condensed tannins compared to the first retentate, thereby producing the decolorized muscadine grape pomace extract with a tannin content that is lower than the clarified extract.
US Pat. No. 10,967,035

AQUACULTURE FEED ADDITIVE

HP Ingredients Corp., Br...

1. A marine feed additive comprising from 2% to 7% (w/w) andrographolide and from 70% to 98% (w/w) dried whole seaweed comprising insoluble plant material.
US Pat. No. 10,967,036

COMPOSITION COMPRISING AN ONION EXTRACT AND LIPOSOMES

HRA Pharma, Chatillon (F...

1. A method for treating a scar in a subject in need thereof, comprising topically administering once a day on the scar to treat the subject, an effective amount of a composition comprising:(a) an onion (Allium cepa) extract,
(b) liposomes, have a unilamellar structure with a diameter in the range of from 50 to 450 nm as measured with Photon Correlation Spectroscopy, and
(c) at least one compound selected from the group consisting of allantoin, hyaluronic acid and panthenol,
wherein at least a portion of the onion extract is encapsulated in the liposomes, and
wherein the composition is in the form of a gel.